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Flow cytometry (FC) is an advanced diagnostic technique widely used in human medicine 
to confirm, classify and stage hematopoietic neoplasms (HNs): it supplies an objective 
evaluation of the size and internal complexity of the cells and identifies the antigenic 
pattern expressed by each cell, which is specific for cellular lineage and maturative stage. 
FC is presently spreading also in veterinary medicine and is mostly used to confirm the 
diagnosis and determine the immunophenotype of canine HNs. 
Aim of this study was to apply FC to the study of specific clinical pathological features of 
canine HNs. In particular, we focused on three points:  
1) staging of diffuse large B-cell lymphoma. We validated a FC technique to assess 
peripheral blood and bone marrow infiltration by neoplastic cells and proved its 
prognostic value. 
2) antigen aberrancies. We investigated the prognostic role of specific antigen 
aberrancies in canine lymphomas and found the dogs with CD4+CD8+ T-cell 
lymphomas had a poorer prognosis compared to other T-cell aberrant lymphomas. 
In addition, we highlighted an important diagnostic role for antigen aberrancies in 
canine small clear cell lymphoma. 
3) CD44 expression. We proved that CD44, which has a role in the pathogenesis and 
dissemination of many human and canine neoplasms, is expressed at different 
degrees on neoplastic cells from different canine HNs, with acute leukemias 
showing the highest degree of expression. 
Overall, our results suggest that FC can be a useful tool not only to confirm the diagnosis 
and assess the immunophenotype of canine HNs, but also to assess clinical pathological 
aspects and additional prognostic parameters specific for the neoplastic subtype identified. 
 




Hematopoietic neoplasms, which are some of the most represented neoplasms in 
dogs, are a heterogeneous group of diseases that originate from the clonal expansion of 
different hematopoietic cells (either lymphoid or myeloid) in lymphoid tissues, in the bone 
marrow or less commonly in other non-lymphoid tissues. On the basis of the lineage and 
stage of maturation of the neoplastic cells, and of the site where neoplasia first arises, 
hematopoietic neoplasms can be subdivided into acute and chronic leukemias, of different 
lineages, and lymphomas. 
The dog is presently given some attention as a possible animal model for human 
non-Hodgkin lymphomas (NHL). Indeed, the classification of canine NHL has been 
compared to the human one and many similarities between the two species have been 
highlighted (Fournel-Fleury et al, 1997). 
Compared to traditional animal models, dogs show some advantages, including: 
 dogs play a useful tool as sentinel hosts for cancer, possibly leading to early 
detection of carcinogens hazards in the environment. In recent years, their 
quality of life has improved, particularly thanks to improvement in veterinary 
cares and nutrition, resulting in a longer survival and an increased probability 
of experiencing spontaneous diseases of old age, including cancer. Dogs 
share the same environment with humans and are therefore exposed to 
pollutants and carcinogens, but they have a shorter lifespan compared to 
humans. As a consequence, the latency period between exposure to 
potential carcinogens and cancer development is shorter (Van der Schalie et 
al, 1999; Backer et al, 2001) 
 dog is an immune-competent host developing spontaneous diseases. In 
addition to the clinical, clinical pathological and histological correspondence, 
also genomic instability is similar between canine and human NHL (Thomas 
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et al, 2001; Thomas et al, 2011). The correlation between genetic factors and 
development and progression of canine NHL is more significant because the 
confounding effect of human genetic heterogeneity is not present in purebred 
dogs. Although cytogenetic studies in canine hematopoietic neoplasms are 
only at an embryonic stage compared to those published in human medicine, 
some abnormalities shared by the two species have been reported so far 
(Hahn et al, 1994; Thomas et al, 2003; Pelham et al, 2003; Breen and 
Modiano, 2008; Gaurnier-Hausser et al, 2011) 
 dog can represent a great model for preclinical stage of anticancer drug 
development. This is a highly expensive and time-consuming process, a 
critical part of which is the demonstration of the antitumor efficacy in a 
relevant tumor model in vivo. Because of the lack of gold standard 
treatments, pet owner may have the opportunity to enroll their pets in new 
clinical trials being potentially of benefit in terms of improved quality of life 
and prolonged survival. In addition, the regulation for the development of new 
drugs in pets is not as strict as for humans and owners’ informed consent is 
often enough for recruitment of dogs. Additionally, in dogs, cancer 
progresses faster than in humans and clinical trials are completed earlier, 
allowing assessing toxicity and efficacy data in a shorter time (Marconato et 
al, 2013). 
 
Unfortunately, however, many gaps still have to be filled in the study of canine 
hematopoietic neoplasms, concerning pathogenesis, diagnosis, prognosis and therapeutic 
protocols specific for each subtype. 
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2- FLOW CYTOMETRY 
Flow cytometry (FC) is a technique for qualitative and quantitative assessment of 
multiple parameters of individual cells or particles in complex cells suspensions. Presently, 
it is commonly used in human oncology for confirmation of diagnosis and assessment of 
immunophenotype in lymphoid and non-lymphoid malignancies (Wood et al, 2007; 
Barrena et al, 2011). 
FC is nowadays spreading in veterinary medicine, as well, and is mostly used for 
the diagnosis and classification of canine hematopoietic neoplasms (Comazzi and Gelain, 
2011; Reggeti and Bienzle, 2011; Joetzke et al, 2012). 
 
2.1- TECHNICAL ASPECTS 
Flow cytometers capture light scatter properties and light emitted by individual cells 
labeled with fluorescent antibodies. Cells or particles are submerged in a fluid medium and 
pass one-by-one through a cell where are interrogated by light, either from a lamp or from 
one or more lasers of defined wavelengths; light scatters and emission signals are then 
captured by specific detectors. 
Specimens for FC have to be sampled as a fluid (peripheral blood, bone marrow, 
effusions) or to be transformed into cell suspensions by means of different techniques. The 
cell suspension is ejected into the center of a sheet fluid, usually a buffered saline solution, 
which achieves a laminar flow under pressure and will carry the cells in a conduits system 
through the cytometer. By means of mechanical tools, cells are placed in the core of the 
laminar flow and narrowed to a single line in order to make them passing into the analysis 
point and being hit by the light stream one-by-one. The optical signals created by the 
interaction between the light stream and the cell are captured by photo detectors and 
converted into electrical signals: 
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 a photo detector is located at 0.5° in the path of the light stream and captures 
only the light diffracted at low angles (forward scatter, FSC). The light 
captured by this photodiode is proportional to the cross-sectional area of the 
cell and to the refractive index of the membrane: FSC is therefore considered 
an index of the cell volume; 
 a photo detector is located at 90° and captures the light scattered by the cells 
at high-angle (side scatter, SSC). The light captured by this photodiode is 
proportional to the internal complexity and the surface texture of the cell: 
SSC is therefore considered an index of the cellular complexity; 
 additional photo detectors are equipped with filters that capture specific 
wavelengths. These signals are usually relatively weak and require 
photomultiplier tubes to generate a useful signal. 
Electric signals generated by conversion of optical signals can be directly captured 
on a linear scale, as typical for FSC and SSC, or amplified on linear or logarithmic scale, 
as typical for fluorescence channels. 
 
A consensus on labeling techniques has never been reached and procedures may 
largely vary from laboratory to laboratory. However, authors agree that pre-analytic quality 
of the sample strongly influence FC analysis, particularly when cellularity and cell viability 
are concerned. Indeed, some authors suggest to assess the cellularity of the sample via 
an automated blood cell counter prior to immunolabeling and to adjust the concentration to 
approximately 10,000 cells/l (Comazzi and Gelain, 2011). To preserve cell integrity and 
antigenic expression, samples for FC should be fresh: labeling of cells within 24 hours 
from sampling is essential for effective immunophenotyping (Jalla et al, 2004). Aspirate 
from lymph nodes can be collected in PBS if FC is performed within a few hours. 
Otherwise, tissue culture media such as RPMI 1640 should be preferred, possibly 
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supplemented with protein sources such as fetal bovine serum or plasma (Gibson et al, 
2004). 
If FC is performed to evaluate nucleated cells populations, RBC need to be 
removed before analysis. Indeed, although the size and light scatter of RBC differ from 
those of leukocytes, they outnumber leukocytes by about 1000-fold in the blood. Many 
different techniques can be used to eliminate RBC; however, osmotic lysis with water, 
ammonium chloride solutions or other buffers is more likely than density gradient methods 
to preserve leukocytes in their native state (Nguyen et al, 2007). RBC lysis is mandatory 
for bone marrow specimens’ analysis, too. On the contrary, it could be not necessary for 
slightly blood contaminated samples such as lymph node aspirates, effusions or 
cerebrospinal fluid (Duque et al, 2002; Gibson et al, 2004; Gelain et al, 2008). 
Once the pre-analytic quality of sample has been verified and RBC have been 
eliminated, immunolabeling with monoclonal antibodies can be performed. As a first step, 
cells are usually incubated or washed with a buffer containing serum to block non specific 
antibody binding to the cell surface: this step is particularly relevant when indirect antibody 
staining protocols are adopted. Next, cells are divided into aliquots for negative and 
positive controls and for staining with antibodies of interest. Negative controls may be 
unstained cells, cells incubated with just fluorochrome-linked secondary antibody or cells 
incubated with fluorescent antibodies directed to epitopes not expressed by the population 
of interest. Positive controls are cells incubated with a fluorescent antibody directed to an 
epitope which is known to be expressed by the population of interest. Which negative 
and/or positive control use is highly dependent from the cytometric assay and the 
preference of the operator (Hurley, 2010). 
Antibody incubations are generally performed at 4° for 15 to 30 minutes. The 
optimal concentration of each antibody has to be determined by titration and if antibody 
combinations are applied, these need to be optimized in concert. Antibodies can be 
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directly conjugated to fluorochromes (direct staining) or may be used in a 2-step procedure 
(indirect staining), which includes sequential incubation with a primary antibody, removal of 
unbound antibody, and incubation with a secondary fluorochrome-conjugated antibody. 
Application of a direct staining procedure reduces incubation steps, time requirement and 
potential for non-specific antibody binding (Stewart and Stewart, 2010). 
Intracellular staining of antigens can be performed, as well, but it is a more 
laborious procedure than cell surface antigen detection and artifacts are more common 
(Sachdeva and Asthana, 2007). Indeed, cells have to be fixed and permeabilized to allow 
antibodies entry the cytoplasm and additional negative and/or positive controls are 
needed. Once again, procedures vary among laboratories, but as a rule only directly 
conjugated antibodies are suitable for intracellular staining. 
 
After incubation with antibodies, cells can be immediately acquired at the flow 
cytometer or preserved with formaldehyde- or alcohol-based fixatives for delayed analysis. 
Unfortunately, fixed cells have different light scatter properties and reduced fluorescence 
emissions, thus immediate acquisition should be preferred (Shapiro, 2003). Data analysis 
system may vary among laboratories but 10,000 cells are usually acquired for each tube. 
For each cell, the flow cytometer records a numeric value for FSC, SSC and for each 
fluorescence channel. Data can thereafter be visualized by dot, density or contour plots or 
histograms (fig 2.1). Selecting regions of cells with distinct features (gating) allows 
restricting analysis to specific population of cells. For example, fluorescence could be 




Figure 2.1: representation of flow cytometric data obtained from peripheral blood sample of an 
healthy dog. A, B, C: forward VS side-scatter; all acquired events are shown; a first gate (R1) was 
set to exclude debris; a second gate (R2) was set including only small-sized cells with low cellular 
complexity (lymphocytes). A: dot plot: every dot represents a single cell. B: density plot: color 
shades represent frequency of events; the paler is the color, the higher is frequency of events. C: 
contour plot: lines of different colors surround areas with different frequency of events. D: 
histogram; only cells included in R1 are shown according to the degree of fluorescence after 
staining with anti-CD21 antibody: only a few cells (B-lymphocytes) stained positive (M1) 
 
2.2- APPLICATIONS IN COMPANION ANIMALS ONCOLOGY 
In veterinary oncology, FC is most often applied to companion animals’ 
hematopathology. Immunophenotyping of hematopoietic cells is based on the use of a 
panel of antibodies directed to cell surface or cytoplasmic antigens (clusters of 
differentiation, CD) to characterize cells that appear microscopically similar. Indeed, each 
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cell lineage and maturative stage within the same lineage are characterized by a distinct 
antigenic pattern. 
A great interest is nowadays paid to canine hematopoietic neoplasms, as they are 
one of the most diffuse oncologic diseases in the dog. In particular, although it is quite 
difficult to estimate the real annual incidence in the absence of a tumor registry, canine 
lymphomas comprise approximately 7% to 24% of all canine neoplasms, and 83% of all 
canine hematopoietic neoplasms. On the other hand, frequency of the different forms of 
leukemias is still not clear, even if lymphoid origin seems more common than the myeloid 
one (Vail et al, 2012). 
Immunophenotyping is usually predicated on clinicopathological evidence of 
putative neoplastic cells either on cytological preparation from solid tissues (suspect 
lymphoma) or on peripheral blood or bone marrow smears (leukemias): indeed, FC can be 
performed to assist the classification of these diseases but it should never replace 
diagnosis based on cytological and/or histological examination.  
In human medicine, an antigen is considered expressed if >20% of the gated 
population stains positive for it (Zeppa et al, 2004); unfortunately, no similar guidelines 
exist in veterinary medicine. As a rule, if a high proportion of the putative neoplastic cells 
shares the same immunophenotype, this is considered a persuasive evidence for 
neoplasia, but does not confirm clonality. Molecular analysis of gene receptor 
rearrangement should be performed to demonstrated clonality in lymphoproliferative 
diseases (Burnett et al, 2003).  
 
2.2.1- CANINE LYMPHOMA 
Phenotype is one of the most important prognostic factors in canine lymphomas 
(Ponce et al, 2004; Vail et al, 2012). Although morphological appearance can be 
considered suggestive of immunophenotype (Fournel-Fleury et al, 1997), it should be 
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always confirmed by additional tests, such as immunocytochemistry, 
immunohistochemistry or flow cytometry. FC is nowadays routinely performed on lymph 
node aspirates for the diagnosis, classification and immunophenotyping of canine 
lymphomas. 
The first report of FC immunophenotyping of lymph node aspirates in a large 
number of dogs with lymphoma goes back up to 2001, when Culmsee and colleagues 
described the FC phenotype of 30 canine lymphoma cases. All analyzed samples had 
sufficient quality and cellularity for FC analysis and diagnosis of lymphoma was always 
confirmed. B-cell phenotype was more common than T-cell phenotype. Since then, other 
studies have been published describing FC features of canine lymphoma subtypes 
(Sozmen et al, 2005; Wilkerson et al, 2005; Gelain et al, 2008). In particular, Gelain and 
colleagues investigated whether FC could add more objective data about morphology of 
lymphoma cells to conventional cytology (Gelain et al, 2008). Authors described the FC 
properties of lymph node aspirates from 50 dogs with lymphoma. Each lymphoma case 
had been classified according to the Kiel updated classification based on lymph node 
cytological preparations. No statistical difference in FC properties among lymphoma 
subtypes and no correlation between cellular size in cytology and FC was detected. 
Interestingly, authors identified unusual phenotypes, either qualitative or quantitative, in 
64% of the lymphoma cases, particularly when small-cell lymphoma were considered. 
Authors concluded that FC, when used in conjunction with cytology, is a useful technique 
to refine classification of canine lymphomas, since it ads objective morphological 
information on a higher number of cells and allows identification of the phenotype, thus 
confirming neoplasia in ambiguous cases as low-grade, small cell lymphomas. 
As highlighted by Gelain and colleagues, FC allows a quantitative evaluation of the 
expression of single antigens on the neoplastic cell surface. Whether unusual or aberrant 
phenotypes are associated to different prognosis has still to be defined. Recently, one 
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study investigated the influence on survival of Class II Major Histocompatibility Complex 
(MHCII) or CD34 expression by neoplastic cells in canine B-cell lymphomas (Rao et al, 
2011). Based on FC results, expression of CD34 appeared as a dichotomous variable 
(that is, cells were easily divided into positive and negative), while MHCII exhibited a range 
of expression and cases had to be arbitrarily divided into two groups based on the median 
fluorescence intensity, with low and high MHCII expression, respectively. Based on the 
results of this study, MHCII had a negative association with mortality and relapse (low-
MHCII group had shorter disease free interval and survival); on the contrary, CD34 was 
not associated with prognosis. In addition, cases in which neoplastic cells had a very large 
size (high FSC) also had a poorer outcome. Taken together, these results suggest that FC 
can be useful not only in confirming diagnosis and immunophenotype of lymphomas, but 
also in evaluating distinct variable associated with prognosis. 
Although it is still not clearly described in literature, FC is often used to stage canine 
lymphoma. WHO clinical staging system recognizes five different stages of lymphoma 
based on organ invasion and two substages related to clinical signs (Vail et al, 2012), but 
techniques used for stage assessment largely vary among studies.  
A recent study wondered if aspirates from non-lymphoid tissues in dogs are feasible 
for FC analysis (Joetzke et al, 2012). Authors examined by FC peripheral blood and bone 
marrow samples and aspirates from lymph nodes, spleen and liver from dogs with 
lymphoma and from healthy dogs. Only 12 out of 245 samples were not suitable for FC 
analysis due to a low cellularity: among them, 9 were liver aspirates, 1 a spleen aspirate 
and 2 bone marrow samples. Authors conclude that since sample from all different tissues 
included in the study were suitable for FC, this technique may aid in the detection of extra 
nodal lymphoma involvement in dogs. However, all samples were stored at 4° C and 
processed within 12 hours from collection and only three antibodies were tested (CD45, 
CD3 and CD21); thus, further studies should be performed to confirm suitability for FC of 
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aspirates from extra nodal tissues after a longer storage and for staining with a wider panel 
of antibodies. 
The detection of peripheral blood and bone marrow infiltration has traditionally relied 
on cytological evaluation (Ponce et al, 2004; Flory et al, 2007; Flory et al, 2011). However, 
such an approach lacks specificity since the neoplastic cells, particularly those in low 
grade lymphomas, are difficult to distinguish from normal and reactive lymphocytes. 
Morphological assessment may also lack sensitivity and diagnostic accuracy, since slight 
marrow infiltration is difficult to observe and inter-observer variation can occur (Comazzi 
and Gelain, 2011). FC has been suggested in human medicine as a useful ancillary 
technique to be used in conjunction with histopathology to increase sensitivity and 
specificity and detecting bone marrow infiltration by lymphoma cells (Hanson et al, 1999; 
Talaulikar et al, 2009). Bone marrow histopathology is not routinely performed in veterinary 
medicine, mostly because of clinicians’ reluctance, but FC has been used in some studies 
to quantify bone marrow infiltration (Grindem et al, 1998; Marconato et al, 2008; 
Marconato et al, 2011). However, use of FC for canine lymphoma staging is still far from 
being standardized. 
In conclusion, today FC is largely used on lymph node aspirates to confirm and 
classify canine lymphomas. Recent studies are aimed to extend the application of FC to 
the staging of lymphomas by detecting neoplastic cells in non-lymphoid tissues. 
 
2.2.2- CANINE LEUKEMIAS 
The main applications of FC for canine leukemias are the confirmation of neoplasia, 
the discrimination between acute or chronic leukemias or leukemic lymphomas, the 
identification of the cell lineage involved and the identification of prognostic features. Until 
recently, the classification of canine leukemias was dependent upon cell morphology and, 
in some instances, the use of cytochemical staining. However, these techniques have 
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been superseded in human medicine by immunophenotyping by FC, which is now 
considered the gold standard for classification of leukemias (Jennings and Foon, 1997). 
As a rule, clinical presentation is an important aid in solving the differential among 
leukemic lymphomas, chronic leukemias and acute leukemias. Indeed, dogs with leukemic 
lymphoma usually present with generalized painless lymphadenopathy (or with any other 
primary lesion in case of extra nodal lymphoma); other clinical signs are variable and 
depend on the extent and location of the neoplasm; blood and/or bone marrow infiltrations 
can occur, but they only rarely cause peripheral cytopenias. Dogs with chronic leukemias 
are usually asymptomatic, even if owners can report lethargy and decreased appetite; 
lymph nodes are usually not or minimally enlarged; in most cases, severe leukocytosis is 
found during routine hematologic checks; concomitant mild cytopenias can occasionally be 
found; at blood smear evaluation, neoplastic cells appear as normal mature cells (in most 
cases lymphocytes, only rarely myeloid cells). Dogs with acute leukemias have an acute 
onset of aspecific clinical signs such as lethargy, inappetence and weight loss, persistent 
fever, pallor and petechiae; moderate lymphadenopathy is common but not always 
present; blood cell count reveals a variable leukocytosis combined with severe non 
regenerative anemia and thrombocytopenia; at blood smear evaluation, neoplastic cells 
have an immature aspect and recognizing cellular lineage is usually difficult or impossible 
by morphological evaluation alone (Young and Vail, 2012). 
 Clinical presentation and routine blood analysis including smear evaluation, 
although strongly suggestive of the final diagnosis, are not conclusive and do not allow 
identifying the lineage involved: thus, further tests have to be performed. From the time FC 
is available on large scale in veterinary medicine, it has been used to get a final diagnosis 
in many case reports and in a few studies including a large number of dogs. 
 Most case reports refer of acute myeloid leukemias. Clinical presentation and 
morphological description of neoplastic cells in these cases are usually suggestive of 
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acute leukemia and sometimes myeloid origin can be supposed based on cytological 
evaluation alone. However, only FC immunophenotyping with a large antibody panel 
allows to make a definitive diagnosis and to identify the specific cellular lineage involved 
(Ameri et al, 2010; Comazzi et al, 2010; Tomiyasu et al, 2011; Valentini et al, 2011; 
Figueiredo et al, 2012).  
 In 2008, Williams and colleagues described the immunophenotype of circulating 
lymphoid cells in 202 dogs with lymphoproliferative disease characterized by 
lymphocytosis and investigated its prognostic relevance. Authors were able to identify four 
main phenotypic groups: CD8+ T-cells, CD21+ B-cells, CD5+CD4-CD8- aberrant T-cells 
and CD34+ undifferentiated cells. Median survival was compared among phenotypic 
groups, and CD34 expression appeared to predict a poorer prognosis, while no difference 
was found among the remaining three phenotypic groups. CD34 is considered a marker of 
acute leukemias (Vernau and Moore, 1999). Dogs included in the study by Williams and 
colleagues had peripheral lymphocytosis with apparently mature lymphocytes: the 
presence of cases with CD34+ cells and poor outcome suggests that morphologic 
description alone can be insufficient to discriminate acute and chronic leukemias. 
Additional findings from the study of Williams and colleagues include: 1) among cases with 
CD8+ T-cell lymphocytosis, a higher lymphocytes count was associated to poorer 
prognosis; 2) among cases with CD21+ B-cell lymphocytosis, large cell size was 
associated to poorer outcome and to the presence of lymphadenopathy at diagnosis. 
Unfortunately, authors did not distinguish between primary leukemias and leukemic 
lymphomas, thus their results could have been biased by the inclusion of dogs with 
different diseases. 
 Similar inclusion criteria were applied in a study by Tasca and colleagues in 2009. 
In this study, immunophenotype of 210 dogs with hematologic neoplasia was described. 
Based on morphology and FC, authors subdivided cases in acute lymphoid leukemias 
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(ALL), acute myeloid leukemias (AML), chronic leukemias (CLL) and leukemic high-grade 
lymphomas (HGL). Authors reported that most cases of ALL and HGL were of B-cell 
phenotype whereas most cases of CLL were of T-cell phenotype and that cytopenias 
(anemia, thrombocytopenia and neutropenia) were more common and more severe in ALL 
and AML cases compared to CLL and HGL; in addition, thrombocytopenia was more 
common in T-cell than in B-cell HGL. Authors concluded that a standard CBC can be 
useful in suggesting the type of hematopoietic neoplasm. Unfortunately, the phenotypic 
pattern of each subgroup is not well defined in the study. Indeed, cases were diagnosed 
as AML based only on positive staining for CD34 and CD45 and negative staining for two 
lymphoid markers (CD3 and CD79): these cases would have better been classified as 
undifferentiated acute leukemias, since no myeloid marker was tested confirming the 
lineage of origin. In addition, authors declared they differentiated ALL from CLL and HGL 
based on the expression of CD34; however, CD34+ lymphomas (Rao et al, 2011) and 
CD34- acute leukemias (Ameri et al, 2010; Comazzi et al, 2010; Tomiyasu et al, 2011; 
Valentini et al, 2011; Mylonakis et al, 2012) have been reported, thus this marker should 
not be considered conclusive by itself to solve the differential. 
Clinical pathological and epidemiological features of dogs with confirmed leukemia 
were assessed via a prospective study by Adam and colleagues, in 2009. Lymphoma 
cases were not included in the study. Cases were subdivided into three groups based on 
the final diagnosis (ALL, AML, CLL). Differently from the study of Tasca and colleagues, 
CD34 was considered suggestive of acute leukemias, but some cases were classified as 
ALL or AML based on morphological evaluation of the blood smear, irrespective of the 
results of CD34 staining; in addition, negative staining for lymphoid markers was not 
considered conclusive for AML, but cells from these cases had to stain positive for at least 
one myeloid marker. Based on the results of Adam and colleagues, dogs with ALL had 
more cytopenias and more severe neutropenia and thrombocytopenia compared to dogs 
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with CLL, whereas the severity and prevalence of cytopenias was not different between 
ALL and AML cases. Total white blood cell count was not different among the three 
groups. Percentage and absolute number of atypical cells detected via smear evaluation 
was higher in ALL than in AML cases. The advent of immunophenotyping has facilitated 
more accurate leukemias classification than even before and has led to question the 
knowledge based upon the less firm foundations of the diagnosis in older studies. Still, 
results from Adam and colleagues support previous statements that acute leukemias give 
rise to more profound cytopenias than chronic ones. However, the main advantage of FC 
appears to be the clear identification of the lineage of neoplastic cells in acute leukemias, 
more than the confirmation of acute leukemia itself. Further prospective studies should be 
performed to assess the prognostic relevance of different phenotypes in acute leukemias. 
On the contrary, confirming the diagnosis of chronic leukemias is mainly based on 
exclusion of any possible cause of leukocytosis. Indeed, cells keep the morphological 
appearance of normal mature cells and are easily identified at smear evaluation. 
Immunophenotyping by FC can aid in distinguishing non-neoplastic from neoplastic mature 
lymphocytosis determining the phenotypic diversity of circulating cells (Avery and Avery, 
2007). 
FC has been used in a recent study to define the immunophenotype of CLL in dogs 
and its prognostic influence (Comazzi et al, 2011). Forty-three dogs were included in the 
study, and subdivided into three groups based on FC phenotype: B-CLL (CD21+), T-CLL 
(CD3+CD8+) and atypical-CLL (any other phenotype, including CD3-CD8+, CD3+CD4-
CD8-, CD3+CD4+CD8+, CD3+CD21+). Among all clinical pathological variables 
considered, only immunophenotype was associated with survival: dogs with T-CLL had the 
longest survival and a 3-fold higher and 19-fold higher probability of surviving than dogs 
with B-CLL and atypical-CLL, respectively. In addition, among B-CLL cases old dogs 
survived longer than younger dogs and among T-CLL cases anemic dogs had a shorter 
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survival than dogs without anemia. Although preliminary and obtained via a retrospective 
study where treatment was not standardized, these results suggest that immunophenotype 
is of great importance for dogs with CLL. Phenotypic groups in this study were created 
evaluating the contemporary expression of different antigens on the surface of neoplastic 
cells, a characteristic easily evaluable only via FC. 
In conclusion, application of FC to canine leukemias is presently aimed at 
confirming diagnosis and cellular lineage. In addition, it brings prognostic information when 
used in CLL cases: whether this can be applied to acute leukemias as well has still to be 
determined. 
 
2.2.3- RNA-DNA CONTENT ANALYSIS 
In addition to detecting proteins with fluorescent antibodies, FC can be used to 
analyze nucleic acid content and to characterize DNA or RNA synthesis, cell cycle stages, 
apoptosis, necrosis and individual chromosomes. In oncology, DNA analysis can serve as 
an adjunct to estimate the proliferating tumor fraction or aneudiploid states, which may 
relate to prognosis of tumors. 
Nucleic acid dyes significantly fluoresce only when bound to their target. A range of 
nucleic acid stains is available, with different emission wavelength, cell membrane 
penetration and nucleotide specificity. The most widely used nucleic acid stain is 
propidium iodide which is unable to penetrate into viable cells allowing exclusion of non-
viable cells from analysis and distinction of necrosis from early apoptosis (Smolewski et al, 
2002; Schmid et al, 2007). 
Cells of an organism have a consistent amount of nuclear DNA unless they undergo 
meiosis, mitosis or apoptosis; cells populations containing nuclei with increased or 
decreased DNA content (aneuploid) are commonly observed in human tumors and, in 
many instances, reflect malignant properties of the tumor. For in vitro assessment of the 
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cell cycle, it is often desirable to quantify the proportion of cells in diploid stages (G0/G1), 
in the S-phase (with an intermediate amount of DNA) and in the G2/M phases, where DNA 
synthesis has been completed to the tetraploid stage (Huang et al, 2005). 
Tumor DNA or RNA content analysis is not routinely applied in veterinary clinical 
oncology. However, it has been used in some research studies. In theory, a high 
proportion of cells containing asymmetric DNA content (aneuploid cells) should reflect 
gross genetic abnormalities of a tumor, and an increased proportion of cells synthesizing 
DNA should reflect rapid tumor growth (Hall, 2004). Accordingly, aneuploid cells have 
been identified by FC in canine mammary tumors (Rutteman et al, 1988), prostatic 
carcinoma (Madewell et al, 1991), plasma cell tumors (Frazier et al, 1993), transitional 
cells carcinomas (Clemo et al, 1994) and hemangiopericytoma (Kang et al, 2006). DNA 
ploidy was also analyzed by FC in canine lymphomas (Teske et al, 1993). In this study, 
aneuploidy was detected in 20 out of 94 lymphoma cases and the mean S-phase fraction 
was significantly higher in lymphomas than in non-neoplastic controls. No difference was 
found in DNA ploidy and S-phase fraction between T- and B-cell lymphomas or among 
different lymphoma histotypes. Finally, neither DNA ploidy nor S-phase fraction were 
correlated to survival. Authors concluded that the frequency of DNA aneuploidy in canine 
lymphomas is similar to that described in human medicine, whereas the absence of 
correlation between DNA ploidy or S-phase fraction and histomorphology or prognosis is in 
contrast with findings in human medicine.  
Other studies found aneuploidy in neoplastic cells, but none of them could find a 
significant correlation with prognosis (Clemo et al, 1994; Kang et al, 2006). Many reasons 
for the limited prognostic significance of aneuploidy are possible, including: admixture of 
multiple non-neoplastic cells (including multinucleated polyploid cells) in analysis, tumor 




2.2.4- FELINE SAMPLES 
Hematopoietic neoplasms are quite common in the cat, too; however, only one 
report has been published about use of FC in feline lymphomas (Roccabianca et al, 2006) 
and the clinical relevance of immunophenotype, which is one of the most important 
prognostic factors in canine lymphoma, has never been described in the cat. Only few 
reports have been published about use of FC to confirm diagnosis and immunophenotype 
of feline leukemias, as well (Tebb et al, 2004; Gelain et al, 2006; Sharifi et al, 2007; 
Campbell et al, 2012). 
Some important differences make feline samples less suitable for FC analysis 
compared to canine samples: 
 differently from the dog, the most common clinical presentation of feline 
lymphoma is a low-grade small cell lymphoma involving the gastrointestinal 
tract (Vail, 2012) which is likely more difficult to be sampled than peripheral 
lymph nodes (that are most commonly involved in canine lymphomas). 
Cytological evaluation of fine needle aspirate of the primary lesion if often not 
sufficient to distinguish among lymphoma (particularly low-grade lymphoma), 
benign hyperplastic or reactive lymphoid conditions. Histopathological 
assessment is required in these cases, as only architectural abnormalities 
and invasiveness can bring to a definitive diagnosis of neoplasia. PARR 
analysis can help refining diagnosis in equivocal cases, but its application 
has been described as being approximately only 80% sensitive for the 
diagnosis of feline lymphoma, whereas specificity has not been defined 
(Avery, 2009). 
 besides biological differences between canine and feline hematopoietic 
neoplasms, the most important limiting factor for the application of FC to 
feline samples is the reduced number of monoclonal antibodies available: 
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this prevents the assessment of precise phenotype and of antigen 
aberrancies. Studies describing the phenotype of feline hematopoietic 
neoplasms and its potential prognostic value are still lacking. Publication of 
such data in the future would perhaps improve the production and validation 
of monoclonal antibodies reacting with feline antigens, and consequently the 
application of FC to the study of feline hematopoietic neoplasms.  
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3- AIM OF THE STUDY 
Aim of the present study was to evaluate some clinical-pathological features of 
canine hematopoietic neoplasms via flow cytometry (FC). Peculiar characteristics and 
advantages of FC will be applied to different specific aims, described one-by-one here 
below. 
 
3.1- CANINE LARGE B-CELL LYMPHOMA STAGING 
Lymphoid neoplastic cells are well characterized by FC, and both cell size and 
immunophenotype can be determined, thus identifying a specific fingerprint of the 
neoplastic cells for each case. Once this has been made, other tissues from the same dog 
can be investigated by FC to detect and quantify the infiltration by the same neoplastic 
cells. This is particularly useful in lymphomas in which other tissues, such as peripheral 
blood (PB) and bone marrow (BM), may be investigated for the presence of the same 
neoplastic cells identified in the lymph node. This detection is particularly easy and specific 
when neoplastic cells have characteristics that clearly distinguishes them from normal or 
reactive lymphocytes, such as large size or aberrant phenotype. 
In this section of the present study, the attention will be paid to large B-cell 
lymphoma (LBCL), the most common lymphoma subtype in the dog. In this particular 
subtype, neoplastic cells are easily distinguishable from normal or reactive lymphocytes 
thanks to their large size. A FC method to quantify PB and BM infiltration will be validated 
and compared to cytological evaluation, and its prognostic value will be assessed via a 
prospective study.  
Based on WHO clinical staging system, canine lymphoma is classified as stage V 
when PB or BM infiltration (or any other non-lymphoid tissue) occurs (Vail et al, 2012). 
However, methods of evaluation are not standardized and the prognostic influence is still 
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not clear: as a consequence, BM evaluation is considered not mandatory under official 
guidelines unless peripheral blood cytopenias are present (Vail et al, 2010). The link 
between PB cytopenias and BM infiltration will be investigated in this section, too. 
 
3.2- PHENOTYPIC ABERRANCIES IN CANINE LYMPHOMAS 
One of the main peculiarities of FC is the possibility to assess the contemporary 
expression of different antigens on the same cellular population, and the subsequent 
identification of antigen aberrancies. In human medicine some specific aberrancies are 
related to different prognosis in specific neoplasms (Jennings and Foon, 1997; Lai et al, 
2000; Gorczyca et al, 2002; Mitrovic et al, 2009), but no data are at the moment available 
in dogs. The detection of aberrant patterns, however, is useful to confirm clonal expansion 
and to accurately check tissue infiltration (Comazzi and Gelain, 2011).  
First aim of this section of the study was to assess the prevalence and the 
prognostic value of specific phenotypic aberrancies detected by FC in canine lymphomas, 
irrespective of the subtype, via a retrospective study. 
Differently from other lymphoma subtypes, cytological evaluation of canine small 
clear cell lymphoma (a T-cell lymphoma) cannot be considered conclusive for neoplasia, 
and further tests have to be performed. In humans, aberrancies are quite common in T-cell 
lymphomas and are considered an excellent diagnostic tool (Jamal et al, 2001; Arun et al, 
2010). In this section of the study, as a second aim, we will retrospectively describe the 
prevalence of aberrancies in canine small clear cell lymphoma and the usefulness of FC to 
confirm the diagnosis of neoplasia when histopathology, which is the gold standard 




3.3- EXPRESSION OF CD44 IN BLOOD FROM DOGS WITH 
HEMATOPOIETIC NEOPLASMS 
FC allows a semi-quantitative evaluation of the expression of molecules on the cell 
surface. Indeed, the more is a molecule expressed by the cells, the higher will be the 
mean fluorescence intensity (MFI) of the antibody specific for that molecule, when 
compared to the MFI of unstained cells.  
This property of FC will be used in the last section of the study to assess the degree 
of expression of CD44 in PB sample from dogs with hematopoietic neoplasms.  
CD44 is being studied in human medicine because of its pathogenetic and potential 
therapeutic role in many neoplasms. It is the main receptor for the hyaluronic acid and 
different isoforms are expressed by the different cells of the organism (Mackay et al, 1994; 
Ponta et al, 1998). It is involved in many cellular processes, such as proliferation, 
migration, survival and apoptosis (Lesley et al, 1993) and could therefore be involved in 
the proliferation and spread in the organism of neoplastic cells. In particular, the degree of 
expression of CD44 has been correlated to a worse prognosis in many hematopoietic 
neoplasms in humans (Hertweck et al, 2011). Some authors opened the way for the 
development of new drugs targeting CD44, by demonstrating that the administration of 
anti-CD44 antibodies can induce cellular differentiation in AML-M0 cell lines (Charrad et al, 
2002).  
Although it has been studied in many different reactive and neoplastic conditions in 
the dog (Moore et al, 1996; Sanchez et al, 2004; Serra et al, 2004; Lin et al, 2009; 
Madrazo et al, 2009; Paltian et al, 2009; Sabattini and Bettini, 2009; Cogliati et al, 2010), 
no study is at the moment available about CD44 expression in canine hematopoietic 
neoplasms. In the last section of present study we focused on the expression of CD44 in 
hematopoietic neoplasms with particular regard for peripheral blood, due to the possible 
role played by CD44 in the systemic spread of the neoplastic cells. 
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4- MATERIALS AND METHODS 
Samples included in the present study were collected and sent by the Oncology 
Service of the Department of Veterinary Sciences and Public Health (University of Milan, 
Milan, Italy; Dr Damiano Stefanello), by the Centro Oncologico Veterinario (Sasso 
Marconi, Bologna, Italy; Dr Laura Marconato), or by private vets for diagnostic purposes or 
routine hematologic analysis to the Laboratory of the Department of Veterinary Sciences 
and Public Health (University of Milan, Milan, Italy) or of the Department of Veterinary 
Science (University of Turin, Turin, Italy; Dr Fulvio Riondato). 
Flow cytometry (FC) was performed on lymph node (LN), peripheral blood (PB) 
and/or bone marrow (BM) samples. LN samples were collected into 1 ml of RPMI, PB and 
BM samples in EDTA tubes. All samples were stored at 4°C and processed within 24 
hours from collection. When not provided by the referring veterinarian, PB and BM smears 
were prepared and stained with May-Grunwald-Giemsa. 
Before processing for FC, all samples were analyzed via an automated hematology 
analyser (Sysmex XT-2000iV; Sysmex, Kobe, Japan) to assess cellularity. 
BM samples were not admitted to the FC analysis if subjectively considered 
excessively hemodiluted by smear evaluation (considering the presence of spicules, 
megakaryocytes and immature cells) and/or by automated count (comparing the number 
of RBC and nucleated cells in PB and BM samples from the same dog).  
PB and BM samples underwent a pre-labeling lysis using a buffer containing 8% 
ammonium chloride to eliminate erythrocytes. This was usually not necessary for LN 
samples as blood contamination was never severe and did not interfere with FC analysis. 
Sample processing for FC analysis was performed as previously described (Gelain et al, 
2008). 
All antibodies utilized for FC were provided by Serotec (Oxford, UK) except for anti-
CD34 that was provided by BD Pharmingen (San Diego, CA, USA), and had been 
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previously titered to define the correct working dilution. Antibody panel applied to each 
sample included: anti-CD3-FITC (clone CA17.2A12), anti-CD5-PE (clone YKIX322.3), anti-
CD4-FITC (clone YKIX302.9), anti-CD8-PE (clone YCATE55.9), anti-CD21-PE (clone 
CA21D6), anti-CD79a-PE (clone HM57), and anti-CD34-PE (clone 1H6). In order to 
properly select cells via a tricolor approach, anti-CD45-FITC or –APC (clone YKIX716.13) 
was included in each tube. 
Samples were finally acquired via a FACScalibur or a BD Accuri C6 flow cytometer 
(Becton Dickinson, San Josè, CA, USA) and data were analyzed via specific software 
CellQuest or CFlow Plus (Becton Dickinson, San Josè, CA, USA). 
 
All statistical analysis were performed using SPSS 19.0 for Windows and results 
were considered significant when p≤0.05. 
Materials and methods for specific aims are described here below. 
 
4.1- CANINE LARGE B-CELL LYMPHOMA STAGING 
FC was utilized to quantify PB and BM infiltration by neoplastic cells in dogs with 
large B-cell lymphoma (LBCL). In a first scatter gram based on forward- (FSC) and side-
scatter (SSC), a gate (R1) was set to exclude debris. In  a second scatter gram based on 
SSC and CD45-fluorescence, a gate (R2) was set including only CD45-positive cells. 
Finally, only cells included in both R1 and R2 were visualized and a FSC versus CD21-
fluorescence scatter gram was drawn. PB and BM infiltration were defined as the 
percentage of large (FSC-H channel higher than 400) CD21-positive cells (large B-cells) 




Fig 4.1: bone marrow flow cytometric scatter grams from a dog with large B-cell lymphoma and a 
moderate (9.6%) bone marrow infiltration by large B-cells. A: all acquired events are shown; a gate 
(R1) was set to exclude debris based on the forward and side scatter properties. B: all acquired 
events are shown; a gate (R2) was set to include only CD45-positive cells (all leukocytes). C: only 
cells belonging to both R1 and R2 are shown; the discriminator was set on the basis of the 
fluorescence of cells incubated with isotypic control, large B-cells are in the upper right quadrant. 
Published in Veterinary Journal, doi:1016/j.tvjl.2013.05.003 
 
 4.1.1- DIAGNOSTIC PERFORMANCES 
To establish the diagnostic performances of this FC method, samples from dogs 
with a final diagnosis of LBCL based on LN cytology, FC and PARR analysis were 
prospectively enrolled.  
PARR analysis was regarded as a gold standard to identify PB and BM infiltrated 
samples, and only PARR-positive PB and/or BM samples were included in the study. 
Additionally, samples from healthy dogs or dogs with diseases other than LBCL were 
enrolled as negative controls.  
A ROC curve was drawn to establish the percentage of large B-cells that best 
distinguishes between infiltrated (PARR-positive) and control samples (from healthy dogs 





4.1.2- COMPARISON BETWEEN FC AND CYTOLOGY 
In order to assess if FC and cytology are interchangeable and give the same results 
about PB and BM infiltration by LBCL, 60 consecutive cases of canine LBCL were 
retrospectively extracted from the database of the Laboratory. Additional inclusion criteria 
were: availability of a CBC by an automated analyser (Sysmex XT-2000iV; Sysmex, Kobe, 
Japan), availability of PB and BM smears stained with May-Grunwald-Giemsa, and 
availability of FC data about LN, PB and BM. 
Cytological infiltration was calculated as the percentage of atypical cells among 100 
nucleated cells on PB smears, and as the percentage of lymphoblasts among 500 
nucleated cells on BM smears. 
Cases were subdivided into four groups based on BM infiltration evaluated by FC 
and cytology, respectively. When FC results were used for classification, group A had <5% 
infiltration, group B from 5 to 10%, group C from 10 to 20%, group D >20%. When 
cytological results were used for classification, group 1 had <5% infiltration, group 2 from 5 
to 10%, group 3 from 10 to 20%, group 4 >20%. 
Cohen’s Kappa value was calculated to assess the agreement between the two 
techniques. 
 
4.1.3- BM INFILTRATION AND PB ABNORMALITIES 
The same cases included in section 4.1.2 were analyzed to check if BM is infiltrated 
by LBCL only in dogs with PB abnormalities, as supposed by official guidelines (Vail et al, 
2010) but never proved. 
PB abnormalities were defined as any hematological value out of internal laboratory 




Mann-Whitney test was performed to analyze the difference in BM infiltration 
between dogs with and without anemia, thrombocytopenia, leukocytosis, lymphocytosis or 
atypical cells, and between dogs with or without any hematological abnormality. 
Generalized Linear Models were used to evaluate the correlation between BM infiltration 
and hemoglobin concentration, platelet, leukocytes, lymphocytes, atypical cells number 
and PB infiltration. 
 
4.1.4- PROGNOSTIC VALUE 
Prognostic value of PB and BM infiltration was investigated via a prospective study. 
To this aim, dogs admitted at the Centro Oncologico Veterinario (Sasso Marconi, Bologna, 
Italy; Dr Laura Marconato) and diagnosed with LBCL on the basis of lymph node cytology, 
FC and when possible histopathology were prospectively enrolled.  
Based on a complete staging workup (consisting of history, physical evaluation, 
CBC and biochemical profile, cytological evaluation of liver and spleen, diagnostic imaging 
of thorax and abdomen, cytological and FC analysis of PB and BM) dogs were assigned to 
a clinical stage according to the WHO staging system (Vail et al, 2012) and treated with 
the same CHOP-based chemotherapy protocol.  
Generalized Linear Models were performed to check the independence of PB and 
BM infiltrations from the following variables, which have shown some prognostic value in 
the literature (Marconato et al, 2011): breed (pure- or mixed breed), gender (male or 
female), and age (< or ≥10 years), weight (< or ≥10 kg), substage (a or b), anemia 
(present or absent), high LDH activity (present or absent) and pretreatment with 
corticosteroids (present or absent).  
Univariate and multivariate Cox’s proportional hazard regression analysis were 
performed to determine any possible relationship between PB or BM infiltration and TTP or 
LSS. When a significant association was detected, all cases were subdivided into two 
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groups based on arbitrary cutoff value of 1%, 3%, 5%, 10%, 15% and 20%. Kaplan-Meier 
curves were drawn for each cutoff and compared by Log-rank test. Finally, hazard ratios 
(HRs) were calculated for each cutoff using a Cox’s proportional hazard regression 
analysis. 
 
4.1.5- LINK BETWEEN PB AND BM INFILTRATION DEGREE 
To establish if PB infiltration can predict BM infiltration, some consecutive cases 
with a final diagnosis of LBCL were retrospectively extracted from the FC database of the 
Laboratory of the Department of Veterinary Sciences and Public Health (University of 
Milan, Milan, Italy). For each case PB and BM infiltration by large B-cells were recorded. 
Different degrees of BM infiltration were arbitrarily selected and ROC curves were 
drawn to identify PB infiltration cutoff values suitable to safely identify BM samples with at 
least 1%, 3%, 5%, 10% and 20% large B-cells, respectively. Sensitivity and specificity for 
each selected PB infiltration cutoff were recorded. 
 
4.2- PHENOTYPIC ABERRANCIES IN CANINE LYMPHOMAS 
4.2.1- PROGNOSTIC VALUE 
Prevalence and prognostic role of specific aberrancies in canine lymphomas was 
evaluated by a retrospective study. The FC database of the Laboratory of the Department 
of Veterinary Sciences and Public Health (University of Milan, Milan, Italy) was 
interrogated over a five-year period. All cases with a final diagnosis of lymphoma were 
extracted and antigenic pattern for each case was recorded.  
Aberrancies were defined as diminished or absent expression of pan-leukocyte 
antigens or antigen specific of the involved cellular lineage, co-expression of antigens from 
different cellular lineages, co-expression or lost of both CD4 and CD8 by T-cells, and 
expression of CD34 in cases in which acute leukemia had been excluded.  
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For aberrant lymphoma cases, referring vets were interrogated and therapy, time-
to-progression (TTP), lymphoma-specific-survival (LSS) and cause of death were 
recorded. Kaplan-Meier curves were drawn and compared by Log-rank test to assess the 
influence of specific aberrancies on TTP and LSS. 
 
4.2.2- DIAGNOSIS OF SMALL CLEAR CELL LYMPHOMA 
To establish the diagnostic role of antigen aberrancies in canine lymphomas, only 
small clear cell lymphoma cases were taken into account, as this morphological 
appearance is considered suggestive, although not conclusive, of T-zone histopathological 
pattern and therefore T-cell phenotype (Fournel-Fleury et al, 1997; Fournel-Fleury et al, 
2002; Ponce et al, 2004).  
Laboratory databases of the Department of Veterinary Sciences and Public Health 
(University of Milan, Milan, Italy) and of the Department of Veterinary Science (University 
of Turin, Turin, Italy; Dr Fulvio Riondato) were interrogated. Cases with a suspect of nodal 
small clear cell lymphoma were selected and cytological preparations of the lymph node 
were revised.  
Inclusion criteria were: high prevalence of small-sized cells with round to slightly 
irregular nuclei and extended, pale cytoplasm; low mitotic index (0-1 mitoses/five fields 
500x). In addition, cases with a final diagnosis of reactive hyperplasia based on lymph 
node cytology, FC and when needed histopathology were included as negative controls. 
The phenotype of each lymphoma case was recorded, and prevalence of specific 
aberrancies was calculated. Aberrancies were defined as diminished or absent expression 
of pan-leukocyte antigens or antigens of the involved cellular lineage, co-expression of 





4.3- EXPRESSION OF CD44 IN BLOOD FROM DOGS WITH 
HEMATOPOIETIC NEOPLASMS 
In the last section of this study, the degree of expression of CD44 by the lymphoid 
population in PB samples from dogs with lymphoma or leukemia was evaluated. To this 
aim, some antibodies were added to the previously described panel: anti-CD44-FITC 
(clone IM7), anti-CD14-PE (clone TUK4), and anti-CD11b-PEcy5 (clone m1/70), anti-
MPO-FITC (clone 2C7). These were all provided by Serotec (Oxford, UK) except anti-
CD44 that was provided by BD Pharmingen (San Diego, CA, USA) and anti-CD11b that 
was provided by eBioscience (San Diego, CA, USA). 
Besides neoplastic samples, PB samples from healthy dogs and dogs with non-
neoplastic diseases were included as controls.  
Diagnosis of acute or chronic leukemia was made on the basis of clinical signs, 
CBC, smear evaluation and FC immunophenotype. Positive staining for CD34 was 
considered suggestive but not conclusive for acute leukemia; when differential with 
leukemic lymphoma could not be solved, cases were not included in the study. 
Acute leukemias were classified as lymphoid (ALL) if stained positive for any 
lymphoid antigen (CD3, CD5, CD4, CD8, CD79a, CD21) and negative for all myeloid 
antigens (CD14, CD11b, MPO), as myeloid (AML) if stained positive for any myeloid 
marker and negative for all lymphoid markers, and as unclassified (AUL) if stained 
negative for all lymphoid and myeloid antigens. 
Chronic leukemias were classified as T-CLL if stained positive for T-cell markers 
(CD3, CD5, CD4 or CD8) and negative for B-cell markers (CD21 and CD79a), as B-CLL if 
stained positive for B-cell markers and negative for T-cell markers, as atypical-CLL if any 
other phenotype was detected (Comazzi et al, 2011). 
For each sample, the population of interest was gated based on morphological 
properties using a FSC versus SSC scatter gram where only CD45-positive cells were 
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shown. CD44 mean fluorescence intensity (MFI) was calculated as the ratio of MFI of 
stained cells/MFI of unstained cells.  
Kruskal-Wallis test was performed to compare CD44 MFI among different disease 
groups (acute leukemias, chronic leukemias, lymphomas, reactive controls, healthy 
controls) and among different phenotypes within the same disease group. Mann-Whitney 
test was performed to compare CD44 MFI between T- and B-lymphocytes in healthy 





5.1- CANINE LARGE B-CELL LYMPHOMA STAGING 
 5.1.1- DIAGNOSTIC PERFORMANCES 
Overall, thirty-one consecutive cases were prospectively enrolled to determine the 
diagnostic performances of FC to quantify PB and BM infiltration in canine LBCL. Among 
them, 15 dogs had LBCL and 16 were negative controls, including 3 healthy dogs, 4 dogs 
with Leishmaniasis, 2 dogs with Evans’ syndrome, 2 dogs with T-cell lymphoma, 1 dog 
with disseminated histiocytic sarcoma, 1 dog with cutaneous mast cell tumor and 3 dogs 
with reactive lymph node hyperplasia of unknown origin.  
PB samples were available for 29 dogs: 14 (48.3%) dogs with LBCL and 15 (51.7%) 
negative controls. Overall mean percentage of large B-cells in PB samples was 
6.47±16.72% (median 1.77%; min-max: 0.15-83.60%). Among lymphoma cases, mean 
percentage of large B-cells was 12.0±23.18% (median 2.25%; min-max: 0.32-83.60%). 
Among negative controls, mean percentage of large B-cells was 1.31±1.17% (median 
0.85%; min-max: 0.15-4.29%). In four negative control samples (3 healthy dogs and 1 dog 
with cutaneous mast cell tumor), large CD21-positive cells also had a high cellular 
complexity (high SSC). When these cases were excluded from analysis, mean percentage 
of large B-cells in negative controls was 0.77±0.54% (median 0.72%, min-max: 0.15-
1.81%). 
When ROC curve was drawn including all control samples, an AUC of 0.812 was 
found, and 1.56% was identified as the best cut-off to distinguish between positive and 
negative samples, having an 85.7% sensitivity and a 73.3% specificity. When ROC curve 
was drawn excluding the four control sample with large CD21-positive cells with high 
cellular complexity, the AUC increased to 0.912 and the best cut-off identified was 1.50%, 
having an 85.7% sensitivity and a 90.9% specificity. 
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BM samples were available for 20 dogs: 11 (55%) dogs with LBCL and 9 (45%) 
negative controls. Overall mean percentage of large B-cells was 11.17±20.45% (median 
1.04%; min-max: 0.12-73.6%). Among lymphoma cases, mean percentage of large B-cells 
was 20.00±24.57% (median 12.58%; min-max: 0.83-73.6%); among negative controls, 
mean percentage of large B-cells was 0.39±0.26% (median 0.33%; min-max: 0.12-1.02%).  
When ROC curve was drawn, an AUC of 0.990 was found, and 1.04% was 
identified as the best cut-off, having a 90.9% sensitivity and a 100% specificity.  
 
 5.1.2- COMPARISON BETWEEN FC AND CYTOLOGY 
Sixty consecutive cases were extracted from the database of the Laboratory to 
compare FC and cytological results about PB and BM infiltration by LBCL. 
 At PB smear evaluation, atypical cells were found only in 5 (16.7%) cases, 
accounting for 1% of all nucleated cells in one case, 4% in two cases, 15% and 72% in 
one case each. Atypical cells found were usually medium to large sized, with high 
nucleus/cytoplasm ratio, slightly basophilic scant to moderate cytoplasm, round or irregular 
nucleus with finely reticular chromatin and occasional prominent nucleoli. In the five cases 
with atypical cells, FC infiltration was 0.13%, 1.80%, 5.4%, 1.96% and 80.41%, 
respectively. Due to the reduced number of cases with atypical cells, agreement tests 
between FC and cytology were not performed. 
In fourteen cases, BM smear quality was subjectively considered not sufficient for 
evaluation, mostly due to bad preparation or preservation. Among the 46 remaining cases, 
cytological infiltration was <5% in 22 (47.8%) cases, between 5 and 10% in 11 (23.9%), 
between 10 and 20% in 6 (13%) and >20% in 7 (15.2%). Although all BM samples had 
sufficient quality for FC evaluation, analysis was restricted to the 46 for which also 
cytological evaluation was possible: among them, FC infiltration was <5% in 31 (67.4%) 
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cases, between 5 and 10% in 3 (6.5%), between 10 and 20% in 4 (8.7%) and >20% in 8 
(17.4%). Combined results from cytology and FC are shown in table 5.1.  





 <5% 5-10% 10-20% >20% Total 
<5% 19 8 3 1 31 
5-10% 2 1 0 0 3 
10-20% 0 2 2 0 4 
>20% 1 0 1 6 8 
Total 22 11 6 7 46 
Table 5.1: distribution of 46 dogs with LBCL based on FC and cytological BM infiltration 
 
5.1.3- BM INFILTRATION AND PB ABNORMALITIES 
The same cases included in section 5.1.2 were analyzed to assess if there is a link 
between BM infiltration and peripheral cytopenias. 
Among 60 dogs included, thirty (50%) had at least one PB abnormality, including: 
moderate anemia (17 cases, 56.7%), thrombocytopenia (15 cases, 50%), leukocytosis (12 
cases, 40%), lymphocytosis (11 cases, 36.7%), presence of atypical cells (5 cases, 
16.7%). Fourteen (46.7%) cases had multiple abnormalities. No dog had lymphopenia or 
granulocytic abnormalities.  
Among cases with hematological abnormalities, PB infiltration was <5% in 18 (60%) 
cases, between 5% and 10% in 3 (10%), between 10% and 20% in 1 (3.3%) and >20% in 
8 (26.7%); BM infiltration was <5% in 16 (53.3%) cases, between 5% and 10% in 1 (3.3%), 
between 10% and 20% in 5 (16.7%) and >20% in 8 (26.7%). 
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Thirty dogs did not have any hematological abnormality. Among them, PB infiltration 
was <5% in 20 (66.7%) cases, between 5% and 10% in 7 (23.3%), between 10% and 20% 
in 3 (10%) and >20% in no one case; BM infiltration was <5% in 21 (70%) cases, between 
5 and 10% in 5 (16.7%), between 10% and 20% in 3 (10%) and >20% in 1 (3.3%) case. 
Median PB infiltration among all cases was 2.82% (min-max: 0.00-80.41%). Median 
BM infiltration among all cases was 3.05% (min-max 0.03-74.50%). PB and BM infiltration 
for each case are shown in fig 5.1. 
 
Fig 5.1: flow cytometric blood (white columns) and bone marrow (black columns) infiltration by 
large B-cells in 60 dogs with large B-cell lymphoma. A significant correlation was found between 
blood and bone marrow infiltration degree (p=0.022). 





On the basis of Mann-Whitney test, BM infiltration was significantly higher in dogs 
with thrombocytopenia (p=0.002), leukocytosis (p=0.032) and lymphocytosis (p=0.000). 
On the other hand, there was no significant difference in BM infiltration between dogs with 
or without anemia or atypical cells and between dogs with or without any hematological 
abnormality (tab 5.2). 
 
Peripheral blood abnormality 
Number of 
cases (%) 
BM infiltration (%) 
Median min-max 
Low hemoglobin concentration 17  (28.3) 3.03 0.3-74.5 
Normal hemoglobin concentration 43 (71.7) 3.07 0.03-48.62 
Low platelet count 15 (25) 18 0.35-74.5 
Normal platelet count 45 (75) 2.49 0.03-27 
High leukocytes number 12 (20) 21.55 0.34-74.5 
Normal leukocytes number 48 (80) 2.58 0.03-51.42 
High lymphocytes number 11 (18.3) 24.43 1.2-74.5 
Normal lymphocytes number 49 (81.7) 2.2 0.03-51.42 
Presence of atypical cells 5 (8.3) 1.35 0.3-74.5 
Absence of atypical cells 55 (91.7) 3.25 0.03-71.26 
Any abnormality 30 (50) 3.97 0.13-74.5 
No abnormalities 30 (50) 2.58 0.03-22.4 
Table 5.2: bone marrow infiltration in different groups of dogs with large B-cell lymphoma, 






Generalized Linear Models showed a significant correlation between BM infiltration 
and platelet count (p=0.012) and PB infiltration (p=0.022): BM infiltration was negatively 
correlated to platelet count and positively correlated to PB infiltration. Interestingly, 
however, in some cases involvement was noticeably higher in bone marrow than in 
peripheral blood (fig 5.1). No significant correlation was found between BM infiltration and 
hemoglobin concentration, leukocytes, lymphocytes and atypical cells number. 
 
 5.1.4- PROGNOSTIC VALUE 
Forty-six dogs with LBCL were prospectively enrolled at the Centro Oncologico 
Veterinario (Sasso Marconi, Bologna, Italy; Dr Laura Marconato) to evaluate the 
prognostic value of BM infiltration quantified by FC. There were 33 (71.7%) purebred and 
13 (28.3%) mixed breed dogs. Twenty-four (52.2%) dogs were males and 22 (47.8%) were 
females. Median age was 8 years (min-max: 3-15 years). Median weight was 28.1 kg (min-
max: 2.6-69 kg). Seventeen (36.9%) dogs received low-dose prednisone for a median of 
12 days (min-max: 4-18 days) before being referred but in all cases it had been 
discontinued for at least 3 days before admission at the Centro Oncologico Veterinario. 
Thirty-one (67.4%) dogs were asymptomatic and 15 (32.6%) showed clinical signs at 
admission. Sixteen (34.8%) dogs had a moderate anemia and 30 (65.2%) had high LDH 
activity. 
All dogs were treated with the same CHOP-based chemotherapy protocol. Thirty-
eight (82.6%) dogs obtained lasting complete remission (CR) within 24 hours of the start of 
treatment; 1 (2.2%) dog obtained CR within 24 hours but progressed 24 days later; 2 
(4.3%) went into partial remission (PR) but one progressed after 19 days; 5 (10.9%) dogs 
experienced progressive disease (PD). Among dogs that achieved lasting CR, 31 (81.6%) 
relapsed during the study period, 5 (13.2%) were still in CR at data analysis closure, 2 
(5.3%) died for causes unrelated to their lymphoma after 20 and 112 days respectively, 
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still in CR for lymphoma. The dog with lasting PR relapsed after 34 days. Overall median 
time-to-progression (TTP) was 87 days (min-max: 0-1211 days). 
Six (13%) dogs were still alive and in CR at the end of study, 2 (4.3%) died for 
causes unrelated to their lymphoma, 38 (82.6%) died for PD. Overall lymphoma-specific 
survival (LSS) for all dogs was 188 days (min-max 9-1403 days). 
Median PB infiltration was 3.0% (min-max: 0.2-45%); median BM infiltration was 
3.8% (min-max: 0.2-47.4%). PB infiltration was directly correlated with BM infiltration 
(p=0.000). PB infiltration was significantly higher in dogs <10 years old (p=0.007), in 
females (p=0.009), in symptomatic dogs (p=0.049) and in dogs with high LDH activity 
(p=0.006), whereas it was not associated with breed, weight, anemia or pretreatment with 
corticosteroids. BM infiltration was significantly higher in symptomatic dogs (p=0.000) and 
in dogs with high LDH activity (p=0.002), whereas it was not associated with breed, sex, 
age, weight, anemia or pretreatment with corticosteroids. 
On the basis of univariate Cox’s proportional hazard regression, TTP was 
influenced by BM infiltration (p=0.001), substage (p=0.002), LDH activity (p=0.028) and 
anemia (p=0.044), whereas LSS was influenced by BM infiltration (p=0.000), substage 
(p=0.000) and anemia (p=0.034). In the multivariate analysis, only substage was 
associated with TTP (p=0.002), whereas substage and anemia were associated with LSS 
(p=0.000 and p=0.008, respectively). 
Kaplan-Meier curves were drawn and compared by Log-rank test for BM infiltration 
groups, with arbitrary cutoffs of 1%, 3%, 5%, 10%, 15% and 20% (tab 5.3 and 5.4, fig 5.2 
and 5.3). 
 A cutoff of 1% gave the lowest Log-rank test’s p-value for TTP (p=0.000) and one 
of the lowest for LSS (p=0.003). Median TTP and LSS were 208 and 344 days for dogs 
with BM infiltration <1%, and 64 and 164 days for dogs with BM infiltration ≥1%, 
respectively. Dogs with BM infiltration ≥1% had a 6.7 times (95% CI: 2.2-20.4) higher 
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probability of recurrence and 3.4 times (95% CI: 1.4-8.1) higher probability of death 
compared to dogs with BM infiltration <1%. 
Using a cutoff of 3% (close to the median value in our case series), median TTP 
and LSS were 149 and 322 days for dogs with BM infiltration <3%, and 69 and 155 days 
for dogs with BM infiltration ≥3%, respectively (p=0.004 for TTP, p=0.001 for LSS). Dogs 
with BM infiltration ≥3% had a 3.3 times (95% CI: 1.4-7.6) probability of recurrence and a 














<1 9 2 208 0.000  
≥1 30 5 64  6.70 
<3 15 3 149 0.004  
≥3 24 4 69  3.25 
<5 22 5 118 0.002  
≥5 17 2 43  2.99 
<10 30 6 95 0.033  
≥10 9 1 43  2.30 
<15 31 6 95 0.018  
≥15 8 1 43  2.60 
<20 34 7 95 0.006  
≥20 5 0 34  3.62 

















<1 9 2 344 0.003  
≥1 29 6 164  3.42 
<3 14 4 322 0.001  
≥3 24 4 155  3.59 
<5 21 6 201 0.007  
≥5 17 2 133  2.94 
<10 29 7 200 0.075  
≥10 9 1 164  2.00 
<15 30 7 200 0.033  
≥15 8 1 164  2.36 
<20 33 8 200 0.002  
≥20 5 0 171  4.28 






Fig 5.2: Kaplan-Meier curves representing time-to-progression and lymphoma-specific survival of 
46 dogs with large B-cell lymphoma with <1% (continuous line) and ≥1% (dotted line) bone marrow 
flow cytometric infiltration.  = censored data. 
Published in Veterinary and Comparative Oncology, doi:10.1111/vco.12024 
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46 dogs with large B-cell lymphoma with <3% (continuous line) and ≥3% (dotted line) bone marrow 
flow cytometric infiltration.  = censored data. 
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 5.1.5- LINK BETWEEN PB AND BM INFILTRATION DEGREE 
 Samples from other forty-six dogs with LBCL were analyzed to establish if PB 
infiltration degree can predict BM infiltration degree. Among them, mean PB infiltration was 
9.65±16.48% (median 2.67%, min-max 0.00-80.41%) and mean BM infiltration was 
10.59±17.93% (median 2.51%, min-max 0.03-74.5%). In particular, BM infiltration was 
≥1% in 35 (76.1%) dogs, ≥3% in 21 (45.7%), ≥5% in 15 (32.6%), ≥10% in 12 (26.1%), 
≥20% in 8 (17.4%).  
Results from different ROC curves are shown in Table 5.5. Using a 1% cutoff to 
define positive BM samples, the best PB infiltration cutoff was 3.05%, which discriminated 
positive and negative BM samples with a 60% sensitivity and a 100% specificity. However, 
the best results were obtained when a 10% cutoff was used to define positive BM 
samples: the selected PB infiltration cutoff was 13.41%, which discriminated positive and 




Number (%) of BM samples 




(%) Negative Positive 
1 11 (23.9) 35 (76.1) 3.05 60.0 100 
3 25 (54.3) 21 (45.7) 9.15 52.4 100 
5 31 (67.4) 15 (32.6) 9.17 73.3 100 
10 34 (73.9) 12 (26.1) 13.41 75.0 100 
20 38 (82.6) 8 (17.4) 34.73 62.5 100 
Table 5.5: data from ROC curves drawn to select the PB infiltration cutoff most suitable to 




5.2- PHENOTYPIC ABERRANCIES IN CANINE LYMPHOMAS 
5.2.1- PROGNOSTIC VALUE 
371 consecutive cases with a final diagnosis of lymphoma were retrospectively 
extracted from the FC database of the Laboratory of the Department of Veterinary 
Sciences and Public Health (University of Milan, Milan, Italy) in a five-year period, from 
2006 to 2011. Among them, 260 (70.1%) were classified as B-cell, 110 (29.6%) as T-cell 
and 1 (0.3%) as bi-phenotypic lymphoma in which the lineage of origin could not be 
defined since only a T-cell and a B-cell markers were expressed by the neoplastic 
population. 
In 56 (15.1%) cases, at least one phenotypic aberrancy was detected. Cytological 
preparation from lymph nodes was available only for 23 (41.1%) aberrant cases (8 B-cell 
and 15 T-cell lymphomas). 
Aberrancies were more common among T- than B-cell lymphoma cases (35.5% and 
5.8%, respectively). Prevalence of each aberrancy is shown in table 5.6. In particular, the 
most common aberrancy among T-cell lymphomas was a diminished or absent expression 
of CD45 (more than 18% of cases), whereas the most common aberrancy in B-cell 
lymphomas was the expression of CD34 (3.5% of cases). 
Follow-up data were available for 38 (67.9%) aberrant lymphoma cases (7 B-cell, 
30 T-cell and 1 biphenotypic lymphomas). Unfortunately, therapeutic protocol was not 
standardized among cases: 26 (68.4%) dogs received chemotherapy with different drugs 
and protocols (mostly CHOP-based multidrug chemotherapy), 5 (13.2%) received only 
corticosteroids, and 7 (18.4%) were not treated.  
Thirty (79%) dogs progressed during the study period, whereas 8 (21%) were still in 
remission at data analysis closure. Overall median TTP was 150 (min-max: 0-450 days) 
and 60 (min-max: 0-375 days) days for B-cell and T-cell aberrant lymphomas, respectively.  
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Twenty-eight (73.7%) dogs died for progressive disease during the study period, 
whereas 10 (26.3%) were still alive at data analysis closure. Median LSS was 180 (min-
max: 30-450 days) and 150 (min-max: 7-1020 days) days for B-cell and T-cell aberrant 
lymphomas, respectively.  
The dog with biphenotypic lymphoma was treated with CHOP-based chemotherapy, 
progressed within 11 days and died for progressive disease 73 days after diagnosis.  
 
Phenotypic aberrancy Cases (%) among all 
B-cell lymphomas 
Cases (%) among all 
T-cell lymphomas 
Diminished or absent CD45 3 (1.2) 20 (18.2) 
Expression of CD34 9 (3.5) 1 (0.9) 
Diminished or absent CD5   8 (7.3) 
Diminished or absent CD3   3 (2.7) 
Loss of both CD4 and CD8   9 (8.2) 
Co-expression of CD4 and CD8   6 (5.5) 
Expression of CD21   9 (8.2) 
Expression of CD79a   1 (0.9) 
Diminished or absent CD21 1 (0.4)   
Diminished or absent CD79a 1 (0.4)   
Expression of CD5 2 (0.8)   
Expression of CD3 2 (0.8)   
Table 5.6: Prevalence of phenotypic aberrancies among 259 and 110 dogs with B- and T-





Differences in TTP and LSS between B-cell and T-cell aberrant lymphomas were 
not statistically significant. 
Survival analyses were performed only for aberrancies represented in at least 4 
cases. Only CD4-CD8 double-positive cases showed a significantly shorter LSS, but not 
TTP, when compared to all other T-cell aberrant lymphomas (p=0.014, fig 5.4): median 
LSS was 50 and 180 days, respectively. 
 
 
Fig 5.4: Kaplan-Meier curves representing lymphoma-specific survival in dogs with CD4+CD8+ T-
cell lymphoma (dotted line) and all other aberrant T-cell lymphomas (continuous line). Difference 
was statistically significant (p=0.014) 
 
Although not statistically significant, diminished or absent CD45 expression by T-
cell lymphomas seemed linked to a longer LSS when compared to other T-cell aberrant 
lymphomas (median LSS was 211 and 74 days, respectively). Interestingly, this aberrancy 
was detected in all small clear cell lymphomas (4 out of 4 for which lymph node cytological 
preparation was available) but in one case only out of 11 high-grade T-cell lymphomas. 
49 
 
Finally, CD34-positive B-cell lymphomas had a shorter LSS when compared with 
other B-cell aberrant lymphomas (median LSS was 140 and 270 days, respectively), 
although differences were not statistically significant. 
 
5.2.2- DIAGNOSIS OF SMALL CLEAR CELL LYMPHOMA 
Cases of suspect nodal small clear cell lymphoma were extracted from the 
databases of the Laboratories. After review of the cytological preparations from lymph 
nodes, 26 cases fulfilled the inclusion criteria and were therefore included in this section of 
the study. Besides pathological samples, 8 cases with a final diagnosis of reactive process 
were included as negative controls. 
On the basis of FC immunophenotyping, a lymphoid population showing aberrant 
antigen expression was identified in all samples with suspect small clear cell lymphoma, 
thus allowing a definitive diagnosis of neoplasia. 
Neoplastic cells stained negative for CD45 in 25/26 (96.2%). CD3 and CD5 had 
been tested in 25 and 21 samples and stained positive in 18 (72%) and 19 (90.5%) cases, 
respectively. Thirteen cases (50%) stained positive either for CD4 or CD8, 3 (11.5%) were 
positive for both, 9 (34.6%) were double negative, and in one case (3.8%) two distinct 
CD45-negative populations were identified staining positive for CD4 and CD8, 
respectively. Twenty of 26 (76.9%) samples stained positive for CD21 and 3 of 20 (15%) 
stained positive for CD79a. Results of immunophenotyping for each case are shown in 
table 5.7. Flow cytometric scatter grams from one representative case are pictured in fig 
5.5. 
When reactive controls were considered, all cells in each sample stained positive 
for CD45. FC revealed a mixed lymphoid population composed by CD4-positive T-cells 
(mean 35.9%, min-max 19.0-59.3%), CD8-positive T-cells (mean 12.9%, min-max 8.0-
21.2%) and B-cells (mean 43.5%, min-max 23.0-53.0%). Furthermore, all T-cells stained 
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positive for both CD3 and CD5 and either CD4 or CD8; B-cells stained positive for both 
CD21 and CD79a. 
 
Case nr CD45 CD3 CD5 CD4 CD8 CD21 CD79a 
1 - + + - - + + 
2 - + + - - + + 
3 - - ND - + + - 
4 - - + + - - ND 
5 - + + - - - ND 
6 + - + - + - - 
7 - + + - + - ND 
8 - + + - + + - 
9 - - + - - + - 
10 - - + + + + - 
11 - - + - - + ND 
12 - - - - + + - 
13 - + + - + + - 
14 - + + - + + ND 
15 - + ND - + + - 
16 - + + - - + - 
17 - - + + (33%) + (60%) + ND 
18 - + - - - + - 
19 - + + + + + - 
20 - + - + - + - 
21 - ND + - + + - 
22 - + ND - - + - 
23 - + + - + - - 
24 - + ND - - + + 
25 - + ND - + + - 
26 - + + + + - - 
Table 5.7: flow cytometric immunophenotype of the neoplastic population identified in lymph node 





Fig 5.5: flow cytometric scatter grams of the lymph node of one dog with suspect small clear cell 
lymphoma, showing aberrant antigen pattern. Most cells are CD45-negative (A and C), CD5-
positive (A), CD4 and CD8 double positive (B) and CD21-positive (C). 
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5.3- EXPRESSION OF CD44 IN BLOOD FROM DOGS WITH 
HEMATOPOIETIC NEOPLASMS 
Overall, 145 PB samples were included in this section of the study: 13 (9%) from 
healthy dogs, 7 (4.8%) from dogs with non-neoplastic diseases, 20 (13.8%) from dogs with 
acute leukemias (10 ALL, 6 AML, 4 AUL), 21 from dogs with chronic leukemias (10 T-CLL, 
8 B-CLL, 3 atypical-CLL), 84 (57.9%) from dogs with lymphoma (59 B-cell, 25 T-cell). In 4 
lymphoma cases, it was not possible to define the clinical stage because of the lack of BM 
samples; among the remaining 80 lymphoma cases, 54 (67.5%) were classified as stage 
III (41 B-cell, 13 T-cell) and 26 (32.5%) as stage V (16 B-cell, 10 T-cell). 
Results from CD44 expression (CD44 MFI/unstained cells MFI) analysis are shown 
in table 5.8. 
Mean CD44 expression was significantly different among the disease groups 
(p=0.000). In particular, CD44 expression was significantly lower in healthy dogs than in 
dogs with acute leukemias, chronic leukemias, stage III and stage V lymphomas 
(p=0.000); in dogs with non-neoplastic diseases than in dogs with acute (p=0.001) and 
chronic leukemias (p=0.003); in dogs with stage III and stage V lymphomas than in dogs 
with acute leukemias (p=0.000); in dogs with chronic leukemias than in dogs with acute 
leukemias (p=0.002). Finally, acute leukemias showed the highest CD44 expression, and 
it was significantly higher than in healthy dogs (p=0.000), in dogs with non-neoplastic 
diseases (p=0.001), in stage III and V lymphomas (p=0.000) and in chronic leukemias 
(p=0.002). 
Mean CD44 expression was not different among the three phenotypes of acute 
leukemias, among the three phenotypes of chronic leukemias (although a progressive 
decrease was found in T-CLL, B-CLL and atypical-CLL), between B- and T-cell 








Median Mean standard deviation 
Healthy 13 26.69 35.07 27.89 
Granulocytes 3 307.76 265.55 73.28 
Monocytes 3 204.40 191.83 61.38 
T-lymphocytes 3 20.54 18.55 5.21 
B-lymphocytes 3 18.44 16.68 4.13 
Non-neoplastic diseases 7 141.85 184.93 150.83 
Acute leukemias 20 429.03 400.35 167.39 
ALL 10 407.15 362.91 178.66 
AML 6 459.67 450.15 195.52 
AUL 4 411.75 419.25 88.80 
Chronic leukemias 21 235.28 240.44 131.44 
T-CLL 10 261.97 291.06 157.65 
B-CLL 8 173.45 206.31 75.32 
Atypical-CLL 3 99.08 162.75 120.63 
Lymphomas 84 133.28 156.13 104.03 
B-cell 59 141.85 88.51 148.15 
Stage III 41 147.16 150.06 85.38 
Stage V 16 110.67 119.03 69.69 
T-cell 25 132.22 174.96 134.04 
Stage III 13 132.22 172.02 103.68 
Stage V 10 187.24 209.71 164.04 
Table 5.8: CD44 expression by the neoplastic population of dogs with hematopoietic 





Hematopoietic neoplasms (HNs) are some of the most common oncologic diseases 
in dogs. However, pathogenetic and clinical pathological aspects of canine HNs are still far 
from being completely understood. 
Flow cytometry (FC) has been largely used for the diagnosis, characterization and 
staging of human HNs. This technique is spreading also in veterinary medicine and it is 
increasingly used for the diagnosis and characterization of canine HNs. 
The present study demonstrated that FC can be a useful technique not only for the 
diagnosis and immunophenotyping of canine HNs, but also to study pathogenetic and 
clinical-pathological aspects with clinical relevance. Indeed, we demonstrated that: 
 FC allows the quantification of PB and BM infiltration in canine LBCL with 
great diagnostic performances. BM infiltration can be present even in the absence 
of peripheral cytopenias, influences both TTP and LSS, and can be predicted by PB 
infiltration with an optimal specificity, but an unsatisfactory sensitivity; 
 FC allows the identification of phenotypic aberrancies in canine lymphomas. 
Some specific aberrancies can give prognostic information to the clinician. In 
addition, aberrancies have a 100% prevalence in canine small clear cell lymphoma 
and are therefore of great diagnostic usefulness; 
 FC allows a semi-quantitative evaluation of the expression of molecules on 
the cell surface. Thanks to this peculiarity, we demonstrated that CD44 is expressed 
at higher degrees by neoplastic cells in canine HNs compared to the lymphoid 
population of healthy and reactive controls. Although this result has no clinical 
relevance by itself, it deepens the knowledge of the pathogenesis of canine HNs 
and opens the way to the development of new drugs targeting CD44, which are 




Among canine HNs, lymphoma is the most represented, since it accounts for more 
than 80% of all HNs by itself (Vail et al, 2012). It is no more regarded as a single disease, 
but as an heterogeneous group of diseases with different prognosis. One study, indeed, 
demonstrated that morphological appearance in conjunction with immunophenotype give 
important prognostic information: B-cell lymphomas (which are more commonly high-grade 
lymphomas) bear a better prognosis than high-grade T-cell lymphomas, whereas small-
clear cell T-zone lymphomas are usually characterized by an indolent course and a better 
prognosis (Ponce et al, 2004). The biological basis for the identification of these three 
major groups was recently given by Frantz and colleagues, in 2013: they confirmed by 
gene expression profiling (GEP) that canine lymphomas can be subdivided into three 
major molecular subgroups with prognostic significance (high-grade T-cell lymphomas, low 
grade T-cell lymphomas and B-cell lymphomas). Low-grade B-cell lymphomas appeared 
as a subgroup within the B-cell lymphoma group (Frantz et al, 2013). In addition, a recent 
retrospective study investigated survival of dogs with different lymphoma histotypes, 
stressing the need for a precise pathological diagnosis leading to tailored 
chemotherapeutic protocols (Valli et al, 2013). As a consequence, in the authors’ opinion, 
diagnostic and staging procedures, as well as therapeutic protocols, should be 
differentiated and adapted to the specific properties of each lymphoma subtype.  
 
6.1- CANINE LARGE B-CELL LYMPHOMA STAGING 
The first section of this study was focused only on canine large B-cell lymphoma 
(LBCL). LBCL is the most common lymphoma subtype in the dog (Teske et al, 1994; 
Ponce et al, 2010; Valli et al, 2011). Different cytological entities are included in the “LBCL” 
definition, among which the most common is the high-grade centroblastic polymorphic 
lymphoma, which is composed by a mixture of small blastic cells, medium-sized 
macronucleated cells, centroblasts and immunoblasts; usually, this morphological subtype 
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presents with a diffuse histological pattern (Ponce et al, 2004). LBCL is easily recognizable 
by FC, too: indeed, neoplastic cells in the lymph node are large sized (FSC-H higher than 
400) and stain positive for B-cell markers (CD21 and CD79a) (Gelain et al, 2008).  
 
In the present study, we looked for the infiltration by cells with these characteristics 
in PB and BM from dogs with LBCL, validated this method of quantifying infiltration and 
highlighted its prognostic value. Some points have to be remarked about this method: 
 It was not possible to completely confirm that these cells, when found in PB 
and BM samples, were neoplastic. However, to the authors’ opinion, their 
detection in very low percentages in control samples, including samples from 
dogs with severe systemic conditions such as Leishmaniasis, suggests that 
they are likely neoplastic cells.  Interestingly, in some control dogs, a higher 
percentage of these cells were found in PB (never exceeding 5%) showing 
an elevated cellular complexity, thus resembling more a non-specific 
antibody binding to granulocytes than true large B-cells. Sensitivity and 
specificity of FC in detecting PB infiltration increased by excluding these 
cases from analysis. Therefore, careful analysis of all parameters (including 
SSC) recorded by FC should always be done in order to avoid mistakes. In 
addition, quantification of large B-cells in the PB and BM should never be 
performed without a definitive diagnosis of LBCL and a confirmation of the 
neoplastic cells’ size and phenotype. Furthermore, the presence of large B-
cells in the PB or BM should not be considered conclusive of lymphoma.  
 Based on our results, a flow cytometric percentage >1.04% of large B-cells in 
the BM from dogs with LBCL may be considered conclusive for infiltration 
(100% specificity). Unfortunately, sensitivity for this cutoff was slightly lower. 
This could indicate that minimal infiltration could not be detected via FC but 
57 
 
can still be identified by PARR analysis. The prognostic value of this minimal 
infiltration has still to be understood, and prospective studies with the 
combined use of these two techniques should be performed.  
 We compared results obtained by FC with those obtained by cytology in the 
quantification of PB and BM infiltration. Unfortunately, among 60 cases 
analyzed, atypical cells suggesting PB infiltration could be identified only in 5 
cases, in which FC infiltration varied from negative to >80%. Agreement 
analysis could not be performed on these samples; however, it can be 
derived that the presence of atypical cells at PB smear evaluation should not 
be considered conclusive for infiltration, maybe because of the atypical 
appearance of reactive lymphocytes, and that high degrees of PB infiltration 
should not be excluded based on the absence of atypical cells.  
 Our results revealed only a moderate agreement between cytology and FC in 
the evaluation of BM samples. This could be in part due to the different 
sensitivity and specificity of the two techniques, which are based on different 
methods (morphological VS immunological) and analyze a different number 
of cells (500 VS 10,000). In addition, it is important to underline that we 
expressed FC infiltration as a percentage out of CD45-positive cells instead 
of total nucleated cells, since data in human medicine (Allan et al, 2008) and 
some preliminary results in the dog (Novacco et al, manuscript in 
preparation) showed a disruption of some RBC precursors and immature 
RBC by the RBC lysis solution used during the sample processing for FC. 
RBC precursors and immature RBC express CD45 only at a minimal degree, 
thus even the portion not disrupted by the lysing procedure was not included 
in the gates set for FC analysis. On the other hand, when infiltration is 
quantified by cytological evaluation, it is expressed as percentage of all 
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nucleated cells, including RBC precursors and immature RBC. These 
aspects could bias and reduce the agreement between the two techniques, 
particularly when the myeloid-to-erythroid ratio in the BM is abnormal due to 
erythroid abnormalities. However, in our case series, no sample with evident 
alteration of the erythroid lineage was present. Still, we strongly agree that 
cytological evaluation has to be always performed in conjunction with FC, in 
order to validate FC results and to assess alterations of the other 
hematopoietic lineages. 
 The percentage of BM infiltration obtained by FC could be influenced by 
hemodilution and/or by granulocytic hypo- or hyperplasia. Gross 
hemodilution could influence cytological assessment of BM infiltration, as 
well. Therefore, when cytological evaluation or FC is used for BM infiltration 
assessment, samples should be screened for gross hemodilution to avoid 
misjudgment. Samples with gross hemodilution were not included in the 
present study. However, a mild hemodilution can minimally influence 
percentage of neoplastic cells due to the different concentration of nucleated 
cells in PB and BM. Histopathology would be the only diagnostic tool not 
influenced by blood contamination. Granulocytic abnormalities could 
influence not only FC, but also other techniques such as conventional 
cytology and histopathology. On the contrary, PARR is not affected by the 
granulocytes presence, thus representing a more reliable test for cases with 
granulocytic abnormalities, even if the prognostic value of PARR-positive 
bone marrow sample is still not clear (Lana et al, 2006a). None of the cases 
included in the present study had granulocytic hyperplasia or hypoplasia.  
 The FC method we applied to quantify PB and BM infiltration in LBCL cannot 
be used for other lymphoma subtypes. Indeed, when large T-cell lymphomas 
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are concerned, quantifying all T-cells (CD3+ or CD5+) in PB and/or BM 
would bring to an overestimation of the neoplastic cells number, as they 
would be included different classes of T-lymphocytes (T-helper CD4+ and T-
cytotoxic CD8+). Thus, CD4+ or CD8+ cells should be quantified based on 
the immunophenotype identified in the lymph node. Unfortunately, in the dog 
CD4 is expressed also by neutrophils and this makes it very hard to safely 
identify neoplastic cells in CD4+ cases. CD8+ lymphoma cases, on the 
contrary, do not stumble upon this inconvenience, but in the authors’ 
experience this phenotype is uncommon in the dog. However, use of FC to 
stage this lymphoma subtype should be deepened. On the other hand, as far 
as small-cell lymphomas are concerned, it would be impossible to distinguish 
between neoplastic and normal or reactive lymphocytes in PB and BM 
samples. This problem could be climbed by the presence of aberrant antigen 
expression which represents a specific fingerprint of each lymphoma case 
allowing the identification of the same population in PB and BM from these 
dogs (Comazzi and Gelain, 2011). 
 
BM assessment is considered not mandatory in staging dogs with lymphoma under 
official guidelines, unless peripheral cytopenias are present, even if this relationship has 
never been demonstrated. Another important concern of official guidelines is that 
prognostic value of BM infiltration is still controversial, and it does not drive any clinical and 
therapeutic decision (Vail et al, 2010). The present study offers some preliminary answers 
to these points: 
 Based on our results, BM infiltration is higher in dogs with thrombocytopenia, 
leukocytosis or lymphocytosis, and is negatively correlated to platelet count 
and positively to PB infiltration. Hence, even if a high BM infiltration can be 
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expected in dogs with thrombocytopenia, leukocytosis or lymphocytosis, its 
degree cannot be directly predicted by the number of leukocytes or 
lymphocytes: a heavy BM infiltration can be found both in cases with a slight 
and a strong lymphocytosis. On the contrary, the lower is the platelet count, 
the higher is BM infiltration. No difference in BM infiltration was found, 
instead, between dogs with and without any haematological abnormality. Our 
results suggest that BM status should be assessed even in dogs without PB 
abnormalities, as it is not possible to exclude a high BM infiltration based 
only on PB analysis. Some abnormalities such as thrombocytopenia and 
lymphocytosis are likely to be suggestive of a higher BM infiltration. It should 
be underlined, however, that only few cases in our study had a high BM 
infiltration, which could perhaps result in secondary myelophthisis and 
consequent cytopenias. Therefore, the potential of some blood abnormalities, 
such as anemia, to predict BM status could have been underestimated and 
should be further investigated including a larger number of cases with a high 
BM infiltration. 
 Our results highlight a significant correlation between degree of BM 
infiltration by FC and biological behaviour. Notably, BM infiltration was not 
completely independent from other variables, since it lost significance in 
multivariate analysis and was correlated to substage, which also influenced 
prognosis: this association might reflect wider disease spread. In addition, it 
should be underlined that not statistically significant correlation with 
prognosis at multivariate analysis does not exclude influence on prognosis, 
since this analysis is strongly influenced by the number and type of variables 
included and by the number of samples analyzed. Some previous studies 
reported no association between stage and prognosis (Garrett et al, 2002; 
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Morrison-Collister et al, 2003; Flory et al, 2007), while other reported a 
shorter survival for dogs in stage V compared to dogs in stage III-IV (Lana et 
al, 2006a; Marconato et al, 2011). These differences may be due to the 
inclusion of different lymphoma entities, differing therapeutic strategies and 
to the varying methods and cut-offs used to assess infiltration: therefore, we 
evaluated the diagnostic value of BM infiltration in canine LBCL accurately 
defining the inclusion criteria in order to avoid bias that could interfere with 
results. Indeed, only LBCL cases were enrolled, and all dogs underwent the 
same protocol for full staging and were treated by means of the same 
chemotherapeutic regimen.  
 The identification of a BM infiltration cut-off that can be used to define 
subgroups of dogs with different prognosis might be clinically useful. Based 
on our results, a 1% BM infiltration cut-off is the best to discriminate between 
two prognostic groups. However, this cut-off is very close to the limit of 
detection of FC, and we found large B-cells in healthy dogs and in dogs with 
diseases other than B-cell lymphoma at a percentage close to 1%. As a 
consequence, the value of 3% seems to be a more feasible putative cut-off to 
discriminate two prognostic groups, since it showed the lowest log-rank p-
value for LSS and one of the lowest for TTP, and did not overlap with the 
lower limit of detection of FC. In conclusion, we suggest the use of a large B-
cells cut-off of 1% to discriminate between positive and negative BM 
samples, and of 3% to discriminate between two prognostic groups. 
 
Based on a recent survey (Regan et al, 2012), almost all clinicians require a 
complete blood cell count during canine high-grade lymphoma staging, but only a minority 
require BM aspirate to be performed. A challenging issue is whether PB infiltration could 
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be used in substitution or to predict BM infiltration, even if it did not show a prognostic 
value by itself in our case series. Results from the present study suggest that PB 
infiltration can predict BM infiltration with an optimal specificity (100%), but only a 
moderate sensitivity (ranging from 52.4% to 75.0%). Therefore, the presence of PB 
infiltration could be considered suggestive of BM infiltration, which is a negative prognostic 
factor; on the contrary, an absent or slight PB infiltration is not enough to exclude BM 
infiltration. 
 
Unfortunately, BM histopathology and immunohistochemistry were not performed 
on any of the samples included in the present study. In human medicine, these are 
considered the gold standard technique to assess BM infiltration in lymphoma cases and 
to characterize the pattern of infiltration. On the contrary, only a single study has been 
published in veterinary medicine demonstrating that trephine biopsy is more sensitive in 
detecting infiltration compared to BM aspirate (Raskin and Krehbiel, 1988). This paucity 
could be due to a reduced clinicians’ and owners’ compliance, because of the lack of 
proved clinical benefits in spite of an invasive and expensive procedure. On the other 
hand, BM aspirate is easier to collect and cytology is much cheaper and faster than 
histopathology, even though sensitivity and specificity are lower: therefore, morphological 
evaluation via light microscopy is the most commonly used technique for BM infiltration 
assessment in the dog (Ponce et al, 2004; Flory et al, 2007; Abbo and Lucroy, 2007; Flory 
et al, 2011). FC shares the advantages of cytology, since sampling is made by BM 
aspirate and diagnosis is available within one day from sampling. In addition, the present 
study demonstrated a prognostic value for BM infiltration quantified by FC, at least for 
canine LBCL. As a consequence, including this procedure in the staging work-up would 
not strongly increase costs, but would bring to a more precise prognosis. In addition, it 
should be underlined that studies in human medicine suggest adding FC to histopathology 
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in order to increase sensitivity and specificity in the detection of BM infiltration (Hanson et 
al, 1999; Talaulikar et al, 2009). 
 
6.2- PHENOTYPIC ABERRANCIES IN CANINE LYMPHOMAS 
A great advantage of FC is the possibility to evaluate the contemporary expression 
of different antigens on the same cellular population and detect phenotypic aberrancies. 
Phenotypic aberrancies are largely documented in human lymphomas (Schmidt et al, 
1999; Jamal et al, 2001; Arun et al, 2010), are considered a great diagnostic tool 
particularly for peripheral T-cell lymphomas (Jamal et al, 2001) and, in addition, some 
distinct aberrancies have shown a prognostic role (Jennings and Foon, 1997; Lai et al, 
2000; Gorczyca et al, 2002; Mitrovic et al, 2009). Aberrant antigen expression has been 
reported in canine hematopoietic neoplasms, as well (Wilkerson et al, 2005; Gelain et al, 
2008; Rao et al, 2011). However, very little is known about their prognostic role. One study 
investigated the prognostic role of CD34 expression in canine B-cell lymphomas, but failed 
in detecting any association with disease outcome (Rao et al, 2011). Another study 
investigated the influence of phenotypes on survival time in dogs with chronic lymphocytic 
leukemia, and found that cases with atypical phenotype had the worst prognosis; however, 
this group included mostly cases with NK-like phenotype, which cannot be considered 
aberrant (Comazzi et al, 2011).  
 
Our results highlight that phenotypic aberrancies are not uncommon in canine 
lymphomas, as they accounted for around 15% of cases referred to our laboratory in a 
five-year period. In particular, phenotypic aberrancies were more common in T-cell than in 
B-cell lymphomas, as already reported (Gelain et al, 2008). This could be due to the 
different number of antigens tested for each lineage. Indeed, only two B-cell antigens were 
tested in the present study (CD21 and CD79a), while T-cells were identified by means of 
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four different antibodies (CD3, CD5, CD4, CD8). Including a wider number of antibodies 
could unmask aberrancies in a larger number of cases which are presently classified as 
non-aberrant. Another possible explanation for the different prevalence of aberrancies 
between T- and B-cell lymphomas is that canine B-cell lymphomas are in the vast majority 
represented by diffuse large B-cell lymphoma (DLBCL), which could be less prone to show 
phenotypic aberrancies compared to other lymphoma subtypes. Unfortunately, cytological 
preparation from lymph nodes was available only for a few cases in our series, and 
histopathology had hardly ever been performed, which prevented us from evaluating the 
prevalence of aberrancies among different lymphoma subtypes. 
 
The prognostic information about phenotypic aberrancies obtained in the present 
study could be strongly biased by the fact that treatment was not standardized among 
cases. In addition, the lack of morphological data entailed the classification of cases with 
the same antigen aberrancy in a single group, irrespective of the grade of the malignancy, 
which is an important prognostic factor particularly among T-cell lymphomas (Ponce et al, 
2004). Further studies should be performed, including a larger number of cases with 
complete and standardized diagnostic and staging workup and treatment protocol, in order 
to validate our results. Unfortunately, this would require a multicentric study and several 
years of case enrollment to gain a significant number of aberrant cases. Still, results from 
the present study suggest a possible prognostic role for distinct aberrancies in canine 
lymphomas: 
 A significant influence on survival was detected only when comparing 
CD4+/CD8+ T-cell to other aberrant T-cell lymphoma cases. To the authors’ 
knowledge, no data is available in the literature about the prognostic influence of 
this phenotype in canine lymphomas; however, one study hypothesized that this 
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phenotypic pattern is more frequent in lymphoblastic lymphomas, which is 
associated to a more aggressive clinical behavior (Fournel-Fleury et al, 2002). 
 Among B-cell lymphomas, the most common aberrancy was the expression of 
CD34. This molecule is a membrane glycoprotein present on the cell surface of 
both lymphoid and myeloid precursors and its expression is usually considered 
suggestive of acute leukemia (Vernau and Moore, 1999). Acute leukemia cases 
were not included in this section of the present study, nor were included cases in 
which the differential between leukemic lymphoma and leukemia could not be 
solved. CD34 expression has already been reported in canine lymphoma cases 
(Wilkerson et al, 2005; Rao et al, 2011). Based on our results and on those 
obtained by Rao and colleagues, however, positivity to CD34 in canine B-cell 
lymphomas has no influence on prognosis. 
 Among T-cell lymphomas, on the contrary, CD45 diminished or absent 
expression was the most common aberrancy and seemed to bear a better 
prognosis compared to other aberrant T-cell lymphomas, even if the difference 
was not statistically significant. After evaluation of the small number of 
cytological preparations available, this phenotype resulted more common in 
small clear cell lymphomas, which are associated to a better prognosis (Ponce 
et al, 2004). Furthermore, all small clear cell lymphomas included in this section 
stained negative for CD45. As a consequence, in a second step we investigated 
whether phenotypic aberrancies can have a diagnostic role in canine small clear 
cell lymphomas. 
 
Furthermore, we also highlighted a diagnostic role for aberrancies in canine small 
clear cell lymphomas. This is an indolent lymphoma involving peripheral lymph nodes 
whose diagnosis traditionally relies on morphological criteria: cytologically, a pattern with 
66 
 
highly prevalent population of small lymphoid cells with clear cytoplasm and frequent 
“hand-mirror” shape (small clear cell appearance) is considered suggestive, although not 
conclusive, of T-zone lymphoma (Fournel-Fleury et al, 1997; Fournel-Fleury et al, 2002; 
Ponce et al, 2004). However, while the presence of a single population of immature or 
large cells and numerous mitoses at cytological evaluation can be considered conclusive 
for neoplasia, the distinction between low-grade lymphomas and reactive hyperplasia is 
still challenging and requires further tests for confirmation. Histologically, T-zone 
lymphomas show neoplastic cells expanding the paracortex and medullary cords without 
effacing the nodal architecture; the neoplastic population is composed by small 
lymphocytes with sharp, shallow nuclear indentations, unapparent nucleoli and a moderate 
volume of pale cytoplasm; mitoses are rare (Valli et al, 2006). Different studies have 
proved the importance of immunohistochemistry to confirm the diagnosis and define the 
immunophenotype of T-zone lymphomas (Fournel-Fleury et al, 2002; Valli et al, 2006; Valli 
et al, 2011; Flood-Knapik et al, 2012). Unfortunately, surgical removal of a lymph node for 
histopathological evaluation is poorly accepted by the owners due to the increase of costs 
and the need for anesthesia. On the basis of a recent survey, indeed, only 28% of the 
responding participants recommended lymph node histopathology among staging 
procedures, although only high-grade lymphomas were considered in the survey (Regan 
et al, 2012). 
A faster and less invasive method to distinguish reactive from neoplastic cases is 
the PCR for Antigen Receptor Rearrangement (PARR): the development of one or two 
prominent bands is considered suggestive of clonality. Several attempts have been made 
to set up this technique. Unfortunately, optimal sensitivity and specificity have never been 
reached (Vernau and Moore, 1999; Burnett et al, 2003; Valli et al, 2006; Yagihara et al, 
2007; Chaubert et al, 2010; Keller and Moore, 2012a; Keller and Moore, 2012b). PARR 
results in different histotypes were reported in one study: among eight T-zone lymphomas, 
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only five had a clonal rearrangement (Valli et al, 2006). Therefore, neoplasia cannot be 
ruled out based on negative PARR results and the interpretation of this test should be 
always associated with histopathology and immunohistochemistry. Immunocytochemistry 
on lymph node aspirate smears can be a useful tool to determine B- or T-cell phenotype 
and procedures for automated staining have recently been described in veterinary 
literature (Aulbach et al, 2010). This technique requires a minimally invasive sampling and 
as a consequence could be preferred to histopathology by clinicians and owners; 
unfortunately, it is not suitable for assessment of co-expression of different antigens by the 
same cellular population and therefore it does not allow recognition of phenotypic 
aberrancies, which are one of the most important features in human peripheral T-cell 
lymphomas and are considered a hallmark of clonality and neoplasia allowing flow 
cytometric definitive diagnosis of lymphoma (Jamal et al, 2001; Arun et al, 2010).  
Although aberrancies have been described in human and canine B-cell lymphomas, 
as well (Inaba et al, 2001; Gelain et al, 2008; Wang et al, 2009; Rao et al, 2011), we 
selected only small clear cell lymphomas for this section of the study, not all low-grade 
lymphomas, because T-zone histotype (and therefore T-cell phenotype) can be expected 
in these cases. We reviewed FC immunophenotype of 26 cases of suspect nodal small 
clear cell lymphoma and found a prevalence of 100% for antigen aberrancies, thus 
allowing a definitive diagnosis of neoplasia. Eight cases with reactive hyperplasia served 
as negative controls: cytological preparation from lymph nodes in reactive cases, similar to 
the neoplastic ones, showed a highly prevalent population of small lymphoid cells with a 
moderate number of large blast cells, interdigitating cells and a variable amount of plasma 
cells. Therefore, although useful to discriminate between reactive hyperplasia and low-
grade lymphoma, cytology alone was not sufficient to definitively discriminate between 
reactive controls and small clear cell lymphomas. On the contrary, FC revealed a mixed 
population of small lymphoid cells without any aberrancy in reactive cases, whereas 
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aberrancies were always identified in small clear cell lymphoma cases. Therefore, 
differently from cytology, FC allowed a definitive discrimination between reactive and 
neoplastic cases. 
The most common aberrancies found in our case series were: 
 Loss of the expression of CD45, which was found in all small clear cell 
lymphoma cases but one. On the other hand, none of the reactive samples had 
a CD45-negative lymphoid population. CD45 is a pan-leukocyte marker in the 
dog, with different degrees of expression in the leukocytes subclasses (Comazzi 
et al, 2006). Therefore, the absence of CD45 expression could be considered a 
hallmark of neoplasia. A decreased or absent CD45 expression has been 
previously reported in canine T-cell neoplasms (Gelain et al, 2008; Williams et 
al, 2008). 
 CD21 expression, which was quite frequent in our case series. Despite the 
positivity for this antigen, all cases could be considered of T-cell phenotype, 
because of the small clear cell appearance, which was the inclusion criteria for 
this section of the study and is itself suggestive, although not conclusive, of a T-
zone lymphoma (Fournel-Fleury et al, 1997; Fournel-Fleury et al, 2002; Ponce et 
al, 2004) and because of the contemporary expression of at least one T-cell 
marker. T- and B-cell populations were clearly distinct in reactive samples and 
co-expression of markers from different lineages was never found. CD21-
positivity has already been described in canine T-cell neoplasms in the past 
(Wilkerson et al, 2005). Furthermore, in a recent study GEP analysis identified a 
group of genes, including CD21-gene, expressed at higher levels in T-zone than 
in high-grade T-cell lymphomas (Frantz et al, 2012). 
 Co-expression or loss of both CD4 and CD8, which was detected in about 50% 
of the lymphoma cases, but in none of the reactive controls. Co-expression of 
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CD4 and CD8 is a phenotype suggestive of thymocytes: therefore, the 
percentage of lymphoid cells with this phenotype identified by FC on mediastinal 
masses aspirates drives the differential diagnosis between thymoma and thymic 
lymphoma (Lana et al, 2006b). In the present study, only lymph node samples 
were included, thus excluding a possible thymic origin of the CD4+CD8+ double 
positive cells: therefore, this phenotype was considered aberrant and suggestive 
of lymphoma. Some cases of CD4+CD8+ double positive or double negative 
canine lymphoid neoplasms have been signaled in literature. In particular, these 
phenotypes were found in some cases of unclassifiable high-grade T-cell 
lymphomas (Fournel-Fleury et al, 2002) and in a subgroup of dogs with chronic 
lymphocytic leukemia harboring a poor prognosis (Comazzi et al, 2011). Finally, 
results from the present study show a shorter lymphoma-specific-survival for 
CD4+CD8+ double positive cases compared to other aberrant T-cell 
lymphomas. 
 
Unfortunately, histopathology and immunohistochemistry were available only for a 
few cases: this circumstance could be considered a proof of the reluctance of clinicians 
and owners toward these invasive tests. However, the few cases for which histopathology 
and immunohistochemistry were available had a final diagnosis of T-zone lymphoma, thus 
supporting what already reported in the literature (Fournel-Fleury et al, 1997; Fournel-
Fleury et al, 2002; Ponce et al, 2004). In addition, the lack of histopathological data 
prevented the comparison between different lymphoma subtypes and the evaluation of 
possible relationship between specific FC phenotypes or aberrancies and histotypes. 
Further studies should be performed on a larger number of cases comparing cytological, 
FC and histopathological data, in order to assess if specific aberrancies are 
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pathognomonic of T-zone lymphomas and could therefore be considered for the definitive 
diagnosis of this histological subtype. 
 
In conclusion, results from this section of the study support the use of multi-color FC 
for the diagnosis of canine lymphomas since specific aberrancies can bear prognostic 
information; in addition, FC represents a useful tool to confirm neoplasia and exclude 
reactive hyperplasia when a small clear cell lymphoma is suspected and histopathology is 
not available or permitted. 
 
6.3- EXPRESSION OF CD44 IN BLOOD FROM DOGS WITH 
HEMATOPOIETIC NEOPLASMS 
In the last section of the present study, we used FC to evaluate the degree of 
expression of CD44 on blood cells from dogs with HNs and negative controls and found 
decreasing expressions in acute leukemias, chronic leukemias, lymphomas, reactive 
controls and healthy dogs. 
CD44 is a class I trans-membrane glycoprotein expressed ubiquitously on the 
surface of all cells of the organism (Mackay et al, 1994). The sequence of the CD44-gene 
has been defined in many species, including humans and dogs, is highly conserved and is 
composed by constant and variable exons (Screaton et al, 1992). Constant exons are 
expressed in all isoforms, whereas the expression of different combination of variable 
exons gives rise to several CD44 variables or isoforms (CD44v). In particular, the 
expression of constant but not variable exons causes the production of the so called 
“CD44 standard” (CD44s) (Ponta et al, 1998). Normal hematopoietic cells express almost 
only CD44s (Mackay et al, 1994). CD44 is the main receptor for hyaluronic acid, but can 
interact also with other components of the extra cellular matrix (ECM), including 
fibronectin, collagen type I and type IV, laminin and osteopontin; binding to its ligands 
71 
 
promotes the connection to the cytoskeleton and initiates some intracellular signaling 
cascades that ultimately influence cellular shape, adhesion, migration, proliferation, 
survival, apoptosis and differentiation (Hertweck et al, 2011). CD44 has been largely 
studied in human oncology since its interaction with ECM could be one of the pathogenetic 
mechanisms of metastasis formation and tumor spread, as it can promote both 
extravasation of cells and their arrest in distant sites. CD44 expression has been studied in 
some canine neoplasms, as well (Moore et al, 1996; Serra et al, 2004; Madrazo et al, 
2009; Paltian et al, 2009; Sabattini and Bettini, 2009; Cogliati et al, 2010); however no 
study is available to date regarding CD44 expression in canine HNs. 
 
Based on our results, CD44 is differently expressed in canine hematopoietic 
neoplasms: 
 Acute leukemias showed the highest CD44 MFI. Among canine HNs, acute 
leukemias have the fastest progression and the poorest prognosis (Vail et al, 
2012). This aggressive behavior could be partly due to the high expression of 
CD44 on the cell surface, which could facilitate tissue invasion and organic 
failure. CD44 MFI was not different among the three phenotypic groups of 
acute leukemias (ALL, AML, AUL): therefore, it seems linked more to an 
early stop of maturation than to the cellular lineage involved. 
 In CLL, CD44 MFI resulted significantly higher than in healthy dogs and in 
dogs with non-neoplastic diseases, but lower than in acute leukemias; on the 
opposite, there was no statistically significant difference between CLL and 
lymphomas, irrespective of lymphoma stage. Among CLL, CD44 MFI 
progressively decreased in T-CLL, B-CLL and atypical-CLL, even if 
differences were not significant. Based on the analysis performed on a small 
number of healthy dogs, CD44 MFI was higher in T- than in B-lymphocytes: 
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as a consequence, the higher CD44 MFI in T-CLL compared to B-CLL could 
be due to the higher percentage of T-cells, independently from their 
neoplastic transformation. Interestingly, atypical-CLL had a lower CD44 MFI: 
this could be attributed to a stop of maturation at earlier stages, since CD44 
shows a characteristic pattern of expression during lymphocytes maturation, 
with two waves of down-regulation separated by phases of higher expression 
(Vaskova et al, 2008). A lower maturation of neoplastic cells could explain 
the more aggressive behavior of atypical-CLL compared to T- and B-CLL 
(Comazzi et al, 2011). 
 In lymphoma cases, CD44 MFI was significantly higher than in healthy 
controls and lower than in acute leukemias, whereas no significant difference 
was found with CLL and with dogs with non-neoplastic diseases. No 
significant difference was found between B- and T-phenotypes or between 
stage III and V lymphomas. However, CD44 MFI was slightly higher in stage 
III than in stage V B-cell lymphomas and in stage V than in stage III T-cell 
lymphomas: this could be due to the different percentages of B- and T-cells, 
which seem to express CD44 at different degrees when analyzed in healthy 
dogs. Finally, the lack of significant difference between dogs with non-
neoplastic diseases and stage III lymphomas could be due to an increased 
expression of CD44 on the cell surface of non-neoplastic lymphocytes in PB 
from dogs with lymphoma, which could reflect an immune response of the 
organism against the neoplasm. 
 
In the present study, CD44 MFI was evaluated only on peripheral blood samples, 
not on lymph nodes: this could have influenced the data about CD44 MFI in lymphoma 
cases. Indeed, in these cases, the lymphoid population analyzed was heterogeneous, 
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composed by a mixture of normal lymphocytes and neoplastic cells, whose percentages 
varied from case to case, based on the PB infiltration degree. Lymph node samples had 
been regularly analyzed by FC in order to confirm the diagnosis and immunophenotype of 
lymphoma, but data about CD44 expression were not included in the present study since it 
was not possible to compare them with data from normal or reactive lymph nodes. Studies 
including control lymph node samples are required to evaluate the pathogenetic role of 
CD44 in canine lymphomas, and possibly the prognostic role of different degree of 
expression within the same lymphoma subtype. 
 
To assess CD44 expression, we used the anti-CD44 antibody clone IM7 (BD 
Pharmingen, San Diego, CA, USA). It binds to an epitope of the constant region of CD44: 
therefore, distinction among CD44s and single CD44 variants is not possible. Normal 
hematopoietic cells express almost exclusively CD44s (Mackay et al, 1994), but some 
variants can be over-expressed during neoplastic transformation, especially CD44v6 
(Hertweck et al, 2011). As a consequence, the higher degrees of CD44 expression 
detected in the present study could be due to 1) an increase in CD44s expression; 2) an 
expression of CD44 variants that physiologically are not expressed or expressed at very 
low degrees on the surface of hematopoietic cells; 3) a combination of these two 
situations. Antibodies that specifically bind to each CD44v should be employed to untangle 
this bundle. 
 
In conclusion, results from the last section of the present study show a different 
degree of expression of CD44 among canine HNs, thus supporting its possible 
pathogenetic role. Genetic or epigenetic abnormalities underlying the higher expression of 
this molecule should be investigated. Finally, our results support the research and clinical 
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trials of new drugs targeting CD44, as is presently happening in human medicine (Charrad 





Altogether, results from the present study show that FC is a great tool to study 
some clinical pathological aspects of canine HNs. Furthermore, it can be applied in a 
clinical set up to confirm diagnosis and immunophenotype, and to evaluate additional 
prognostic parameters based on the neoplastic subtype identified (BM infiltration in LBCL, 
specific aberrancies in T-cell lymphomas). 
However, besides its advantages, FC also has some important limitations:  
 as cytology, FC is a great tool to analyze cellular morphology, but does not 
allow to assess the architectural pattern of neoplasms;  
 samples for FC have to be analyzed within a few hours from sampling. 
Presently, new products are being validated which preserve cells for some 
days and therefore facilitate delivery to reference laboratory, but FC analysis 
of archive material is still not possible;  
 flow cytometers and monoclonal antibodies have high costs and specifically 
trained personnel is necessary: as a consequence, FC is usually performed 
only in reference laboratories, and delivering of samples could increase costs 
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During my PhD period, I’ve been involved in other studies, not directly bound to my main 
research project. They will be shortly described here below. 
 
Flow cytometric immunophenotyping of acute erythroid leukemia (AML-M6) in a dog 
Martini V, Stefanello D, Ghisleni G, Novacco M, Aresu L, Proverbio D, Comazzi S. 
Veterinary Clinical Pathology, submitted 
A male, mixed breed, 10-years-old dog was presented with lasting severe pancytopenia 
unresponsive to treatment with different antibiotics and low-dose prednisone. 
Myelodisplastic syndrome (MDS) was diagnosed based on bone marrow cytology. The 
dog was treated with whole blood transfusion and high-dose prednisone, but anemia and 
thrombocytopenia progressed. Within five days, a few unclassifiable immature cells 
appeared on the blood smear. Bone marrow cytology was repeated. More than 60% of the 
cells were rubriblasts or prorubricytes with prominent dyserythropoiesis; among non-
erythroid cells, more than 40% were blasts. Immunocytochemistry and electron 
microscopy confirmed erythroid origin of the predominant cells. These cells were disrupted 
by RBC lyses buffer, thus flow cytometry for immunophenotyping was performed also on 
mononucleated cells isolated by gradient separation. The final diagnosis was acute 
erythroid leukemia (AML-M6). Despite therapy with high-dose prednisone, clinical 
conditions got worse and the dog was euthanatized after 38 days from admission. AML-
M6 is a rare disease in humans. Pancytopenia is usually present, while circulating blasts 
are less common. Recent studies suggest that acute erythroid leukemia, acute myeloid 
leukemia with MDS-related changes and MDS with erythroid hyperplasia are biologically 
related diseases arbitrarily separated into different entities even in the 2008 revised WHO 
classification scheme. Although not rare in cats, only two cases of spontaneous AML-M6 
have been reported in dogs. Clinical-pathological features overlapped those described in 
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humans. Evolution of MDS into AML-M6 could be supposed in this case, supporting recent 
findings in humans. Poor prognosis of AML-M6 was confirmed in all species. 
 
Canine indolent and aggressive lymphoma: clinical spectrum with histologic 
correlation 
Aresu L, Martini V, Rossi F, Vignoli M, Sampaolo M, Aricò A, Laganga P, Pierini A, 
Frayssinet P, Mantovani R, Marconato L.  
Veterinary and Comparative Oncology, epub ahead of print 
Sixty-three dogs with newly diagnosed lymphoma underwent complete staging and 
received the same chemotherapy. Diffuse large B-cell lymphoma was the leading histotype 
(44.4%), followed by peripheral T-cell lymphoma (20.6%). Indolent lymphomas accounted 
for 30.2% of cases. Most dogs with aggressive B-cell lymphoma had stage IV disease. 
Dogs with indolent and aggressive T-cell lymphoma had more often stage V disease and 
were symptomatic. Liver and bone marrow were predominantly involved in B-cell and T-
cell lymphoma, respectively. The clinical stage was significantly related to substage, sex 
and total lactic dehydrogenase (LDH) level. Aggressive B-cell lymphomas were more likely 
to achieve remission. Median survival was 55 days for aggressive and indolent T-cell 
lymphoma, 200 and 256 for indolent and aggressive B-cell lymphoma, respectively. The 
prognosis of advanced indolent lymphoma does not appear to be appreciably different 
from that of aggressive disease. Familiarity with the various histotypes is critical to make 







Evaluation of tyrosine-kinase receptor c-KIT (c-KIT) mutations, mRNA and protein 
expression in canine leukemia: might c-Kit represent a therapeutic target? 
Giantin M, Aresu L, Aricò A, Gelain ME, Riondato F, Martini V, Comazzi S, Dacasto M.  
Veterinary Immunology and Immunopathology 2013;152:325-332 
The tyrosine-kinase receptor c-KIT (c-KIT) plays an important role in proliferation, survival 
and differentiation of progenitor cells in normal hematopoietic cells. In human 
hematological malignancies, c-KIT is mostly expressed by progenitor cell neoplasia and 
seldom by those involving mature cells. Tyrosine-kinase inhibitors (TKIs) are actually 
licensed for the first- and second-line treatment of human hematologic disorders. Aim of 
the present study was to evaluate c-KIT mRNA and protein expression and 
complementary DNA (cDNA) mutations in canine leukemia. Eleven acute lymphoblastic 
leukemia (ALL) and acute undifferentiated leukemia (AUL) and 12 chronic lymphocytic 
leukemia (CLL) were enrolled in this study. The amounts of c-KIT mRNA and protein were 
determined, in peripheral blood samples, by using quantitative real time RT-PCR, flow 
cytometry and immunocytochemistry, respectively. The presence of mutations on c-KIT 
exons 8-11 and 17 were investigated by cDNA sequencing. Higher amounts of c-KIT 
mRNA were found in ALL/AUL compared to CLL, and this latter showed a lower pattern of 
gene expression. Transcriptional data were confirmed at the protein level. No significant 
gain-of-function mutations were ever observed in both ALL/AUL and CLL. Among canine 
hematological malignancies, ALL/AUL typically show a very aggressive biological 
behavior, partly being attributable to the lack of efficacious therapeutic options. The high 
level of c-KIT expression found in canine ALL/AUL might represent the rationale for using 





Reticulocyte enumeration errors with Sysmex XT-2000iV in blood from leukemic 
dogs 
Gelain ME, Paltrinieri S, Martini V, Tvedten H 
European Society for Veterinary Clinical Pathology (ESVCP) 13th Annual Congress. 
Veterinary Clinical Pathology 2012;41:E1-E61 
The Sysmex XT-2000iV hematology analyzer enumerates reticulocytes using a fluorescent 
dye that stains nucleic acids. It subdivides reticulocytes based on staining into low-, 
medium-, and high-fluorescence reticulocytes (LFR, MFR, HFR). The immature 
reticulocyte fraction (IRF) includes MFR and HFR, which increase in dogs with 
regenerative anemia. In humans, an increased IRF due to blast cell fragments in leukemic 
patients has been reported, and increased HFR% without polychromasia in a leukemic 
dog has been described. Aim of this study was to investigate potential errors in reticulocyte 
analysis in blood from leukemic dogs compared with non-anemic controls. Full 
reticulocytes and other automated hematology variables were determined in blood from 35 
leukemic dogs (acute lymphoid leukemia: 8 cases; acute undifferentiated leukemia: 10 
cases; chronic lymphocytic leukemia: 17 cases) and 40 healthy dogs. The Sysmex RET 
and RET-EXT scatter grams were analyzed to investigate the presence of an abnormal 
reticulocyte distribution. The percentage of reticulocytes was higher in leukemic dogs than 
in controls. In 29/35 samples the IRF was above the reference interval whereas the LFR% 
was lower; 20 of these dogs were also anemic. In 13 cases increased IRF was due to 
increased HFR% whereas in 16 dogs both HFR% and MFR% increased. In 18 cases an 
atypical cloud of high-fluorescence events was detected in the scatter grams. An 
inappropriate HFR% may be found in blood from leukemic dogs, likely due to dead cells, 
cell fragments, or altered staining of leukemic cells rather than to a true increase in 
reticulocyte production. This error can be visually detected in the scatter grams. Therefore, 
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Sysmex users should check for errors in the IRF% and other reticulocyte variables in 
leukemic dogs. 
 
Leukemic small cell lymphoma or chronic lymphocytic leukemia in a horse 
Cian F, Tyner G, Martini V, Comazzi S, Archer J. 
Veterinary Clinical Pathology, epub ahead of print 
A 16-year-old, Irish Draf mare was admitted to the referring veterinarian for annual health 
check. A mild generalized lymphadenomegaly was noted. Rectal palpation and transrectal 
ultrasonographic examination revealed prominent mesenteric lymph nodes. A 
transcutaneous abdominal ultrasonographic evaluation was unremarkable. A CBC 
revealed a marked leukocytosis (63.06 x 103/l) and lymphocytosis (58.2 x 103/l) due to 
increased numbers of small lymphocytes. No evidence of anemia or thrombocytopenia 
was found and neutrophil counts were low-normal. Cytologic examination of fine-needle 
aspirates of multiple lymph nodes and a bone marrow aspirate revealed the presence of a 
monomorphic population of small lymphocytes similar to those observed in the peripheral 
blood, suggesting a leukemic small cell lymphoma (SCL) or chronic lymphocytic leukemia 
(CLL). As the lymphadenomegaly and peripheral blood lymphocytosis were present 
simultaneously, the distinction between these 2 conditions was not possible. 
Immunophenotyping by immunocytochemistry and flow cytometry of the lymphoid cells in 
peripheral blood determined a T-cell phenotype. As the horse was clinically stable, no 
treatment was initiated, but regular examinations were undertaken. A CBC repeated 120 
days after the diagnosis showed a marked lymphocytosis (157.6 x 103/l) with no evidence 
of anemia or other cytopenias. The horse was euthanized 194 days after the initial 
diagnosis. Histopathology and immunohistochemistry of submandibular lymph nodes and 
bone marrow confirmed the diagnosis of leukemia SCL or CLL, and a T-cell phenotype. 
SCL and CLL are rare in horses; previous immunohistochemical studies determined that 
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the T-cell phenotype is predominant. To the authors’ knowledge, this is the first report of 
the combined use of immunocytochemistry and flow cytometry in a horse with leukemic 
SCL or CLL. 
 
CD4+/CD8+ ratio in atopic dogs before and after treatment with Ciclosporin A: 
preliminary results 
Cornegliani L, Comazzi S, Beccati M, Martini V, Vercelli A. 
Veterinaria 2012;3:31-37 
Ciclosporin is generally used in veterinary dermatology for the treatment of canine atopic 
dermatitis (CAD), due to its selectively ability to block production of inflammatory cytokine. 
CD4+/CD8+ ratio is considered useful to evaluate immune system for the indirect 
correlation with specific lymphocytic immune response (Th1/Th2 ratio). The aim of this 
prospective study was to evaluate CD4+/CD8+ ratio in atopic dogs before and after 
treatment with ciclosporin A (CsA). Eight dogs with CAD were included and flow cytometry 
was performed on day 0 (V0), day 30 (V30) and 90 (V90) from beginning CsA therapy. 
CADESI (Canine Atopic Dermatitis Extend Severity Index) and VAS (Visual Analogical 
Scale) were assessed at the same time. Healthy dogs were used as control group for 
CD4+/CD8+ ratio evaluation. Statistical analysis was performed with SPSS17 software: 
ANOVA for repeated measures was used for CADESI and CD4+/CD8+ ratio, Friendman 
test for VAS difference analysis. P-value <0.05 was considered statistically significant. 
Results showed a p-value=0.001 for CADESI and VAS, a p-value=0.694 for CD4+/CD8+ 
ratio. Based on our results, CsA statistically decreases CADESI and VAS index improving 
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